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EXPLOITATION OF METABOLIC CHECKPOINTS IN CANCER CELLS 
by 
Deven Patel 
Advisor: Dr. David A. Foster 
During the G1 phase of the cell cycle, normal cells respond to growth factors and 
nutrients prior to entering S-phase to replicate its genome. We previously reported that the growth 
factor-mediated restriction point is distinguishable from a series of late G1 metabolic checkpoints 
mediated by essential amino acids (EAAs), the conditionally essential amino acid glutamine (Gln), 
and mTOR – the mammalian target of rapamycin. Mutations in genes encoding proteins that 
regulate G1 cell cycle progression are observed in virtually all cancers.  We observed that cancer 
cells with K-Ras mutations bypass the late G1 Gln checkpoint when deprived of Gln and instead 
arrest in S-phase.  Significantly, this created a synthetic lethality for rapamycin.  Whereas 
rapamycin arrests cells in late G1, in S-phase rapamycin induces apoptosis.  While depriving cells 
of Gln can be achieved in culture, this is not a viable option in an animal.  However, K-Ras-driven 
cancer cells utilize Gln via a novel transaminase reaction whereby Gln is first deaminated to 
glutamate and then glutamate is deamidated to a-ketoglutarate, with the concomitant conversion 
of oxaloacetate to aspartate.  This transamination reaction can be inhibited by aminooxyacetate, 
which mimics Gln deprivation and causes S-phase arrest – creating synthetic lethality for 
rapamycin. 
Since S-phase arrest created a synthetic lethality for rapamycin, we investigated the 
molecular basis for the S-phase arrest.  We found that S-phase arrest was due to an inability to 
	 v 
generate deoxynucleotides needed for DNA synthesis in the absence of glutamine.  The lack of 
Gln suppressed deoxynucleotides biosynthesis, which in turn induced replicative stress. The 
replicative stress activated the ataxia telangiectasia and Rad3-related protein (ATR)-mediated 
DNA damage pathway, which caused S-phase arrest.  Of significance, aspartate, which is a critical 
metabolite for deoxynucleotides biosynthesis and is generated by the transaminase reaction 
between glutamate and oxaloacetate, rescued the S-phase arrest caused by inhibition of glutamine 
utilization. 
The presence of distinct metabolic checkpoints in late G1 for EAAs and Gln led us to 
look for additional checkpoints that monitor the presence of critical nutrients.  Since lipids are 
critical for membrane biosynthesis, we investigated whether serum lipids were important for G1 
cell cycle progression.  We found that when put in delipidated serum, cells arrest in late G1 at a 
distinct site downstream from the Gln checkpoint and upstream from the mTOR site.  Intriguingly, 
this checkpoint is dysregulated in clear cell renal carcinoma cells.  These cells continue to replicate 
in the absence of lipids until they ultimately starve themselves to death. 
In summary, we have identified a series of late G1 metabolic checkpoints that are 
dysregulated in specific cancer cell lines.  It is speculated that when these checkpoints are 
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Mammalian Cell Cycle 
 
The cell cycle is a series of events that take place in order to duplicate the cell’s DNA 
content and to divide one parent cell into two daughter cells. The mammalian cell cycle is divided 
into several phases as follows: Gap-1 (G1) phase, Synthesis (S) phase, Gap-2 (G2) phase and 
Mitotic (M) phase. During G1 phase, it gets the signals from growth factors and decides whether 
it is appropriate to duplicate the genome. During S phase, cells replicates their genome. During G2 
phase, cells check for any anomalies that could happen during the replication process and verify 
the integrity of the replicated DNA. After G2 phase, cells enter M phase where cytokinesis occurs 
and cells divide themselves into two daughter cells.  
In normal proliferating cells, these events are so tightly regulated by a defense mechanism 
called “Checkpoints” that if anything goes wrong, cells activate this checkpoint machinery and 
halt the cell cycle progression until the damage is resolved. There are several checkpoints across 
the cell cycle phases. The first checkpoint is Restriction point (R) in G1 phase, where the cells 
commit to cell cycle entry and chromosome duplication. The second is DNA damage mediated 
checkpoint in S and G2 phase where it verifies the integrity of the genome that is replicated during 
S phase. The third is in the mitotic phase where it leads to chromosome alignment on the spindle 
in metaphase. The checkpoints act as a control system to validate certain requirements which if 
met, allows the progression into the next phase if not, there will be a pause in the cell cycle 
progression and halt them. (Fig. 1.1) The ability of cancer cells to grow and proliferate 
uncontrollably is a result of a dysregulation in this checkpoint machinery. 
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Figure 1.1- Mammalian cell cycle and cell cycle checkpoints. Different phases of cell cycle and 
progression through the checkpoints. 
If cells are deprived of growth factors prior to R, they exit the cell cycle into a state of 
quiescence known as G0. Anders Zetterberg and colleagues have carefully mapped that the time 
it takes to reach R from mitosis is about 3 to 4 hours- a time course that was consistent for virtually 
all cell lines examined [1-3]. Alongside with growth factors, cells also sense nutrients during G1 
phase of the cell cycle. Studies by Hartwell and colleagues described a site in late G1 in yeast cells 
where, upon absence of nutrients, cells arrest [4]. This site was called START and has been 
referred to as the equivalent of the mammalian R. However, START is not sensitive to growth 
factors as the yeast cells respond only to nutrients availability. This significant difference may 
provide us a clue in order to better understand the confusion as to what R actually represents and 
where R is located in G1. To get through START, cells rely on mammalian/mechanistic Target of 


















yeast and mammalian cells [6, 7]. Blenis’ group and others have shown that treatment with 
rapamycin, an inhibitor of mTOR, arrests cells in late G1 phase [8, 9] at a site that is consistent 
with START. Notably, cells arrested with rapamycin were smaller than their counterparts, [8, 9] 
consistent with a role for mTOR as a nutritional sensor that restricts cell growth in the absence of 
adequate nutrients. Previous studies from our lab have validated this conundrum and shown R and 
START as being distinguishable from one another. We have shown R to be a growth factor-
sensitive site where cells acquire signals from growth factors to avoid quiescence and START 
senses whether there are enough nutrients for a cell to double its mass and divide [10]. Ability of 
rapamycin to arrest cells in late G1 indicates that START may be conserved in mammalian cells 
as a distinct checkpoint that senses nutritional sufficiency. This mTOR- dependent nutrient sensing 
checkpoint could more appropriately be referred to as a “Cell Growth” checkpoint.  
Nutrient Sensing Metabolic and Cell Growth Checkpoints 
 
START was originally defined as a commitment step in late G1 where cells confirm the 
nutrient status prior to committing to replicating the genome and cytokinesis [4, 11]. The lack of 
essential amino acids resulted in G1 cell cycle arrest. It has been shown that re-entry of Swiss 3T3 
cells into cell cycle upon restoring amino acids is significantly faster than when cells have entered 
upon restoring growth factors [12]. Saqcena et al. has provided evidence that the GF-mediated R 
and nutrient sensing metabolic checkpoint are different and distinguishable [10]. Unexpectedly, 
there are a series of nutrient sensing metabolic checkpoints mediated by essential amino acids 
(EAAs) and the “conditionally” essential amino acid, glutamine, in the latter part of G1 phase of 
the cell cycle followed by then cell growth checkpoint mediated by mTOR [10]. It is well 
established that mTORC1 senses EAA [13]. 
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Figure 1.2- Nutrient Sensing and growth checkpoint [14]. After Completing mitosis, the first 
obstacle cells face is to passing R to avoid quiescence. Passage through this site is dependent on growth 
factor signaling leads to Cyclin D expression. After passing R, cells activate signals that indicate 
sufficient materials for the cell to double in mass. This checkpoint is mTOR, which suppresses TGF-
bsignaling, which stimulates the expression of p27, which suppresses Cyclin E-CDK2. 
It is also well known and shown by many groups that mTORC1 activity is stimulated by glutamine 
[15]. Other than EAAs and glutamine, mTORC1 is also responsive to glucose [16], ATP levels 
[17], phosphatidic acid [18] and perhaps lipids. mTOR is not fully active until it senses ATP, lipids 
as well as glucose and so this may explain why nutrient sensing checkpoints mediated by EAAs 
and glutamine are upstream of mTOR-cell growth checkpoint. Thus mTOR might be final 
arbitrator that senses all the nutrient input before entering in S-phase to replicate its genome. The 
metabolic checkpoint downstream from R shown by Saqcena, et al. are similar to the series of 
checkpoints shown in yeast together known as START [4, 19], where nutrients adequacy is 
assessed in an mTOR-dependent manner in yeast [5, 20]. It is likely that R evolved much later than 
START as a means for multicellular organisms to regulate proliferation through intercellular 
communication. 
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Mammalian Target of Rapamycin Signaling 
 
mTOR- the mammalian target of rapamycin is a critical energy and nutritional sensor that 
integrates intracellular and extracellular signals. TOR was originally discovered in yeast [21, 22] 
and was found in mammals several years later [23-26]. mTOR is a serine/threonine protein kinase 
that is conserved throughout evolution [27] and plays a vital role in cell cycle progression, cell 
survival, cell metabolism [28, 29]. mTOR is found to be dysregulated in most cancers and thus 
makes it a good therapeutic target. 
mTOR exists in two complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 
(mTORC2). mTORC1 is comprised of five components: mTOR, the catalytic subunit of the 
complex; regulatory-associated protein of mTOR (Raptor); mammalian lethal with Sec13 protein 
8 (mLST8); Proline-rich Akt substrate 40 kDa (PRAS40); and DEP-domain-containing mTOR-
interacting protein (Deptor) [30]. These different components play a distinct role in mTORC1 
activity. It has been proposed that Raptor is necessary for assembly of the complex and thus for 
mTORC1 activity [31, 32]. The role of mLST8 is somehow unclear but loss of this protein does 
not hinder activity or function of mTORC1 in vivo [33]. PRAS40 and Deptor are known to have 
an inhibitory effect on mTORC1 [30, 34, 35]. Upon activation of mTORC1, it phosphorylates 
PRAS40 and Deptor, which further reduces the binding of these inhibitory proteins to mTORC1 
and consequently further activates mTORC1 signaling. mTORC2 consist of six different proteins: 
mTOR; rapamycin-insensitive companion of mTOR (Rictor); mammalian stress-activated protein 
kinase interacting protein (mSIN1); protein observed with Rictor-1 (Protor-1); mLST8; and 
Deptor. mSIN1 has been known to stabilize the assembly of mTOR and Rictor thus establishing 
the structural basis of mTORC2 [36, 37]. Unlike mTORC1, the role of mLST8 is more influential 
in mTORC2 function, as knocking out this protein affects the stability and activity of the complex 
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[33]. Just like mTORC1, Deptor is also inhibitory to mTORC2 activity [30]. In addition to all these 
proteins, both these complexes interact with phosphatidic acid (PA), a lipid metabolite, that is 
shown to be required for the stability of both the complexes [18, 38-40]. 
As shown in Fig. 1.3, mTORC1 receives signals from growth factors through the activation 
of canonical insulin and Ras signaling pathways. Activation of these pathways leads to 
phosphorylation of TSC2 by Akt [41, 42], by inactivating TSC2, inducing activation of mTORC1.  
Akt can also activate mTORC1 in a TSC2-independent manner by phosphorylation of PRAS40, 
which causes dissociation of PRAS40 from mTORC1 [34, 35, 43]. The energy status of the cell 
also dictates the activity of mTORC1 through AMP-activated protein kinase (AMPK). At low 
energy, AMPK gets activated and phosphorylates TSC2, thus reducing mTORC1 activity [44]. 
Additionally, AMPK can reduce mTORC1 by directly phosphorylating Raptor, causing 
dissociation of complex [45]. mTORC1 senses the presence of amino acids and is activated in a 
PI3K-Akt-TSC2-independent manner [46]. Rag proteins, a family of four related GTPases, interact 
with mTORC1 and are necessary for activation of mTORC1 in the presence of amino acids [47]. 
Activation of mTORC1 leads to activation of various downstream effectors in order to achieve 
cell growth. mTORC1 stimulates protein synthesis by phosphorylating the eukaryotic initiation 
factor 4E (eIF4E)- binding protein 1 (4E-BP1) and the p70 ribosomal S6 kinase 1 (S6K1). The 
phosphorylation of 4E-BP1 thwarts its binding to eIF4E, allowing eIF4E to promote cap-
dependent translation [48].  
The activation of S6K1 leads to mRNA biogenesis, cap-dependent translation of ribosomal 
proteins and elongation through regulation of proteins like ribosomal protein S6 [49]. mTORC1 
also controls autophagy through phosphorylation of unv-51-like-kinase 1 (ULK1) and autophagy-
related gene 13 (ATG13) [50, 51]. mTORC1 also regulates lipid biogenesis by regulating sterol 
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regulatory element binding protein 1 (SREBP1) [52]. Manning, et al has shown that S6K1 
activation by mTORC1 leads to phosphorylation of CAD (Carbamoyl-phosphate synthetase 2, 
Aspartate transcarbamoylase, dihydroorotase), an enzyme involved in de novo pyrimidine 
synthesis [53]. 
 
Figure 1.3- Two complexes of mTORC1 and mTORC2 [54]. mTOR complexes are formed by 
different partners and have distinct downstream effectors. 
On the contrary to mTORC1, very little is known about mTORC2. It has been known that 
mTORC2 kinase activity is increased upon activation of growth factor signaling [55]. mTORC2 
is involved in cell survival, metabolism, proliferation and cytoskeletal organization. Deletion of 
mTORC2 components causes a lethal phenotype, explains its importance in the previously 
mentioned role. One of the important downstream effectors is Akt. Full activation of Akt via 
phosphorylation at Ser308 by phosphoinositide-dependent kinase 1 (PDK1) and Ser473 by 
	 9 
mTORC2 leads to activation of its downstream effectors such as forkhead box protein O1 
(FOXO1) and FoxO3a transcription factors, which controls many genes responsible for 
metabolism, cell cycle arrest and apoptosis [56]. 
 Another downstream effector of mTORC2 is serum and glucocorticoid-induced protein 
kinase (SGK1), which shares homology with Akt [57]. mTORC2 controls the actin cytoskeleton 
by promoting protein kinase C ɑ (PKCɑ) phosphorylation and GTP loading of RhoA and Rac1. 
Rapamycin 
 
Rapamycin, a macrolide antibiotic found in the Eastern Island of South Pacific is a 
naturally produced by the bacterium Streptomyces hygroscopicus. In 1975, it was originally 
defined as an antifungal agent as it caused G1 cell cycle arrest [58] and later it was found to have 
immunosuppressant properties [22]. Rapamycin is an allosteric inhibitor of mTORC1. Rapamycin 
binds with FK506-binding protein of 12 kDa (FKBP12) and interacts with the FKBP12-rapamycin 
binding domain (FRB) of mTOR, causing inhibition of mTORC1 [55]. 
FKBP12-rapamycin cannot interact with mTORC2, thus having no effect on mTORC2 
[59]. However, later it had been shown that chronic treatment of rapamycin inhibits mTORC2 
activity by hindering its assembly formation in a tissue-type dependent manner [60]. Phosphatidic 
acid (PA) activates mTOR by binding to its FRB domain and has been shown to compete with 
rapamycin to bind to the FRB domain of mTOR [39]. 
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Figure 1.4- Structure and Application of Rapamycin 
 
Since rapamycin affects mTORC2 to a much lesser extent than mTORC1, a second 
generation of mTOR inhibitors were developed to inhibit both mTORC1 and mTORC2, namely 
Torin 1, PP242, Ku-0063794, WAY600, AZD8055 [61]. As expected these second-generation 
inhibitors can inhibit cell growth and proliferation in vitro and tumor growth in vivo better than 
rapamycin [62, 63]. They could suppress both mTORC1 and mTORC2. However, the use of 
second generation of mTOR inhibitors could not be widely used due to higher toxicity- the 
concentration of these drugs was not tolerable to patients and produced off-target effects. Since 
rapamycin provides better specificity towards mTOR, it calls for elucidating the complete potential 
of rapamycin. Thus, rapamycin’s potential as an anticancer drug requires further investigation. 
Although the apoptotic and anti-proliferative effects of rapamycin have been demonstrated 
by Vivanco, et al in head and neck squamous cell carcinoma, overall rapamycin has not been 
proven effective against most cancers. As rapamycin has poor solubility, a vast number of 
analogues of rapamycin have been developed and are referred to as rapalogs. In 2007, the rapalog 
temsirolimus was approved by FDA for the treatment of advanced stage renal cell carcinoma, 
Rapamycin	
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making it the first mTOR inhibitor approved for therapy. Recently another analog everolimus was 
approved for the treatment of tuberous sclerosis, an autosomal dominant disorder in the brain [64]. 
It has long been known that low doses of rapamycin are not enough to target 4EBP-1 [65]. High 
doses of rapamycin are required for complete inhibition of mTORC1 [66]. It is postulated that the 
limited efficacy of rapamycin is due to its ability to perform as a cytostatic drug rather than 
cytotoxic. It arrests cells in G1 phase of the cell cycle and growth arrest prevents them from 
undergoing apoptosis. Rapamycin causes TGF-β-mediated cell cycle arrest which is discussed in 
detail in the following section. Another shortcoming of using rapamycin based therapy is it 
activates survival signals by activation of Akt by inhibiting phosphorylation of IRS-1 which will 
be discussed in detail in the following sections. 
TGF-β Signaling 
 
Transforming Growth Factor-β (TGF-β) is a multifunctional autocrine/paracrine growth 
regulator [67]. TGF-β is known to have a role in biological processes like embryonic development, 
wound healing and angiogenesis in almost all type of cells. 
The role of TGF-β is somewhat controversial. Under normal conditions, it restricts cell 
growth, differentiation and cell death [68-70]. TGF-β is a tumor suppressor for early stages of 
cancer and associated with poor patient prognosis and increased frequency of metastasis [71]. 
The binding of TGF-β to the TGF-β receptor II (TβRII) receptor kinase activates via 
autophosphorylation followed by coupling with TGF-β receptor I (TβRI). TβRI then 
phosphorylates Smad family proteins, which are downstream effectors of the TGF-β signaling 
pathways. (Fig. 1.5) Smad-2 and Smad-3 are phosphorylated by TβRI at their C-terminal SSXS 




Figure 1.5- Transforming Growth Factor (TGF-b) signaling. TGF-b regulates the growth and 
proliferation of cells. TGF-b binds with TβRI and dimerization of receptors causes phosphorylation of 
SMAD2. SMAD2 then binds to SMAD4. This complex moves to nucleus and form complexes that 
regulates transcription of cell cycle regulators. 
 
In turn this complex translocates to the nucleus and start the transcription of cell cycle 
regulator proteins such as p27, which has an inhibitory effect on cell cycle progression [72]. TGF-
β is negatively regulated by Smad-6 and Smad-7. TGF-β signaling is often compromised in many 















Figure 1.6- Rapamycin activates TGF-β signaling via inhibition of mTOR (Adapted from [73]) 
As shown in the Fig. 1.6, activation of mTOR has been known to relieve this TGF-β 
signaling and allow cells to progress through late G1 phase of the cell cycle and enter S-phase. 
Thus, when rapamycin is added and mTORC1 is inhibited; that will release this inhibition on TGF-
β signaling caused by an active mTOR and will result in p27 accumulation in cells, leads to G1 
cell cycle arrest [73]. 
Negative feedback loop activation upon rapamycin treatment 
 
 Biological systems maintain homeostasis due to physiological stresses by employing 
certain mechanisms, such as negative feedback. Such a mechanism exists in growth factor 
signaling where it is a universal mechanism for limiting the extent and duration of signaling output. 
Recently, several studies have pursued to determine the implication of feedback regulation of 
pathways that are driven by activated oncoproteins, which are usually constitutively expressed in 
tumors.  Tumor cells are known to be “addicted” to oncoproteins. Amit, et al  has studied the effect 
of EGF-dependent numerous negative feedback components including proteins that downregulate 
ERK and ERK-mediated transcriptional programs [74]. Several other studies have also shown that 
the components involved in the negative feedback loop in EGFR signaling in cancer cells were 
found to be under expressed in tumors. Many drugs have been targeting oncoproteins that 
RAPAMYCINmTOR






downregulate the pathways but also relieve such feedback inhibition of other pathways in the 
network, resulting in resistance to the therapy or activation of survival mechanisms. 
 
Figure 1.7- Rapamycin inhibits S6K1-mediated IRS1 degradation and activates PI3K/Akt pathway 
Such consequence has been extensively studied in recent years and that is the case for drugs 
targeting the PI3K/Akt/mTOR pathway. It had been previously established that IGF/Insulin 
pathways are restricted by the feedback inhibition of the expression of insulin receptor and insulin 
receptor substrates (IRS1,2).  
As shown in the Fig. 1.7, mTOR phosphorylates S6K1, thus activating it, and in the 
process, activated S6K1 phosphorylates the IRS and reduces their interaction with the IGF 
receptors via degradation [75]. As shown by several groups, rapamycin relieved this S6K1- 
dependent feedback loop and activates Akt which then provides survival signals to the cancer cells 
[76, 77]. As the cells were treated with rapamycin, IRS proteins were stabilized and led to 
reactivation of PI3K/Akt axis of the growth signaling pathways. The reactivation of the feedback 
















Metabolic Reprogramming in Cancer Cells 
 Unlike normal proliferating cells, cancer cells are surrounded by a different 
microenvironment where they do not have adequate oxygen and nutrient conditions. As a result of 
this, cancer cells adapt to the hypoxic and hypo-nutrient conditions in order to maintain growth 
and proliferation. This phenomenon of adaptive response is often called “metabolic 
reprogramming” and has been acknowledged as one of the hallmarks of cancer [78]. The Warburg 
effect, also known as aerobic glycolysis, explained by Otto Warburg, is how cancer cells exhibit 
an ability to process glucose into lactate even in the presence of adequate oxygen [79]. It has been 
widely accepted as metabolic reprogramming, and recent advances have established that tumor 
cells also depend on mitochondrial metabolism as well as aerobic glycolysis. Mutations in several 
oncogenes and tumor suppressors have been shown to upregulate many metabolic enzymes, 
resulting in metabolic reprogramming [80-82]. Cancer cells become growth autonomous and 
evade growth factor dependence by gaining mutations in cell signaling pathways responsible for 
growth. Recent advances have shown that over-activation of these signaling pathways alters the 
metabolic signature of these cancer cells. Difference in metabolic profiles in cancer cells, in some 
cases, is responsible for failure to induce therapeutic response. In some cases, metabolites 
themselves can be oncogenic by altering cell signaling and blocking cellular differentiation [83]. 
Metabolism is one of the processes that is required to maintain energy homeostasis for a 
complicated process of growth and a means to provide enough raw materials to generate daughter 
cells. Thus, targeting metabolism is a good strategy to target cancer cells over normal proliferating 
cells. A thorough understanding of altered and adapted metabolism will enable us to find a new 




 Glucose has been critical to the study of cancer metabolism following Otto Warburg’s 
discovery of aerobic glycolysis [84]. The role of glutamine in the cancer metabolism field has 
slowly been appreciated given the part it plays in cell growth and metabolism. Since consumption 
and dependence of glutamine in cancer cells is much higher to maintain energy homeostasis and 
raw materials required to generate two daughter cells, it is considered a “conditionally” essential 
amino acid.  
Glutamine has been known to provide carbon to TCA cycle intermediates as well as 
nitrogen to synthesize nucleotides as well as amino acids [85]. In rapidly dividing cells, citrate, 
synthesized from Acetyl-CoA and oxaloacetate, exits the mitochondria and is used for lipid 
synthesis. This exit creates a need for anaplerotic replenishment of TCA cycle intermediates 
downstream of citric acid. Glutamine has been known to feed into TCA cycle intermediates via 
anaplerosis. 
It does so in following manner: After being transported into mitochondria via transporters 
[86], glutamine is first deaminated to glutamate via a glutaminase (GLS). This glutamate can be 
used in several ways. One, glutamate is converted into ɑ-ketoglutarate via glutamate 
dehydrogenase (GDH), producing ammonia [87]. The other pathway is via glutamate oxaloacetate 
transferase (GOT), where glutamate is converted into ɑ-ketoglutarate (a-KG) with the 
concomitant conversion of oxaloacetate into aspartate. Aspartate is also known to provide the 
backbone for de novo nucleotide biosynthesis. Glutamate-pyruvate transaminase (GPT) also 
transfers nitrogen from glutamate to pyruvate to make alanine and ɑ-ketoglutarate. Apart from 
providing carbon to the TCA cycle intermediates, glutamine also provides nitrogen to synthesize 
nucleotides and non-essential amino acids [85]. 
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Figure 1.8- Glutamine metabolism[88]. Gln is deaminated to glutamate by glutaminase (GLS). Then 
Glutamate can be converted to a-ketoglutarate via either glutamate dehydrogenase (GDH) or 
transamination reaction by glutamate oxaloacetate transaminase (GOT), where it generates aspartate, a 
critical metabolite for nucleotides, amino acids, and NADPH production to maintain redox balance. 
Aminooxyacetate inhibits GOT and inhibit the glutamine utilization in cells. 
Glutamine donates its amide nitrogen directly to the purine and pyrimidine ring structures 
to produce nucleotides, generating glutamate in the cytoplasm [89]. This glutamate then can enter 
mitochondria via malate aspartate shuttle that is usually used to shuttle the electrons across the 
mitochondria in exchange for aspartate. So, cells must generate enough aspartate in mitochondria 
to exchange glutamate through this shuttle. Kimmelman and group has shown that K-Ras mutant 
cells choose the GOT pathway over GDH pathway to generate a-KG and in the process, they 
generate aspartate from oxaloacetate [90]. This study provides significance on how aspartate is 
generated by K-Ras mutant cells to sustain this shuttle. Aspartate generated from glutamine 
metabolism also plays an important role in providing its backbone to nucleotides. Recent studies 
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have also shown aspartate derived from several metabolic pathways as being critical in dividing 
cells for nucleotide biosynthesis, fatty acid metabolism [91], the urea cycle [92], and TCA cycle-
derived citrate [93, 94]. Such versatility makes glutamine metabolism an interesting therapeutic 
option to target metabolically reprogrammed dividing cells. 
DNA Damage Pathway 
 
As briefly explained in the section about mammalian cell cycle, there are checkpoints in S 
and G2 phase of the cell cycle where cells activate pathways to correct any error, that have occurred 
during the process of replication. It provides an extra layer of defense against induction of 
mutagenesis in eukaryotes. Precise duplication of the genome during S-phase is one of the most 
important and vital processes in order to proliferate [95]. It is an irreversible process where once 
the replication fork is formed, they are committed to the process. At this point they arrest in cell 
cycle, and if the damage is not repairable, they undergo apoptosis. Under DNA damage, cells 
invoke an activation of signaling pathways which causes an arrest or apoptosis. These pathways 
get activated in response to either double stranded breaks (DSBs) or single stranded breaks (SSBs) 
of the DNA. The single stranded DNA breaks trigger the ataxia telangiectasia mutated and Rad3-
related (ATR) Kinase pathways and double stranded DNA breaks trigger ataxia telangiectasia 
(ATM) kinase pathways, the master regulators of two major checkpoint pathways [96].  The ATR 
kinase is the principal activator of the replication stress response [96-98]. It is a member of serine-
threonine kinases family, that includes ATM, mTOR, DNA-PK and SMG-1 [99]. ATR induces 
the S-phase arrest via phosphorylation of the Chk1 kinase, which targets Cdc25A phosphatase for 
degradation [100, 101], which is responsible for cell cycle progression through S-phase. The 
activation of Chk1 by phosphorylation via ATR, further phosphorylates p53 at Ser15 site, and 
	 19 




Lipids are large biomolecules that are utilized to synthesize plasma membranes in a newly 
generated cell, signal transduction, and generation of extracellular vesicles. The structure of the 
lipids mainly defines the flexibility of the membranes and can provide resistance to 
chemotherapeutic drugs [103, 104]. Lipid metabolism plays a key role in cancer cell survival and 
proliferation under stressful conditions. In adults, de novo synthesis of lipids is restricted mainly 
to liver and adipose tissues, while the lipid demand, by other tissues are fulfilled by lipids 
circulating in blood. Earlier it was shown that studies done with radio-labeled glucose, lipids were 
found labeled which indicated that tumor cells can utilize their carbon from glucose to synthesize 
their own lipids [105]. Since then, it has been shown that many cancers have overexpression of 
fatty acid synthase (FASN), an enzyme responsible for fatty acid synthesis [106, 107]. Although 
research in lipid metabolism has been mainly focused on lipid anabolism, lipid catabolism is also 
important for cancer cell survival. One such example is monoacylglycerol lipase, which catalyzes 
the release of fatty acids from intracellular lipid droplets, promoting growth and survival [108]. 
Another group has also shown that fatty acid oxidation induces resistance to radiation and 
chemotherapeutic agents [109]. 
 Hypoxia plays an important role in the metabolic reprogramming of cancer cells. Several 
studies have shown that under hypoxic conditions, hypoxia inducing factor-1a (HIF-1a) plays an 
important role in upregulation of glycolysis by induction of glucose transporters [83]. Likewise, 
hypoxic cells choose glutamine over glucose to synthesize fatty acids through upregulating 
reductive carboxylation [83, 110]. In clear-cell renal cell carcinomas (ccRCC), there is 
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constitutively activation of HIFs due to loss of the von Hippel-Lindau (pVHL) tumor suppressor, 
which is required for oxygen-dependent suppression of HIFs [111]. pVHL-null ccRCCs maintain 
HIF-2a expression [112] and that maintains growth of ccRCCs [113]. In ccRCCs, there is a clear 
cell phenotype which is due to presence of intracellular lipid droplets (LDs), which is comprised 
of neutral lipid core containing triglycerides and cholesterol-esters, surrounded by a phospholipid 
monolayer and associated LD surface proteins [114]. There are two well cataloged functions of 
lipid droplets: energy homeostasis and release of lipid species for membrane synthesis during 
proliferation [114]. Enhanced lipid storage has been shown to alter lipid metabolism. Qiu, et al has 
shown that HIF-2a-dependent lipid droplets in ccRCCs plays an important role in maintaining the 
integrity of endoplasmic reticulum (ER), thus suppressing ER stress [115]. Understanding these 
lipid droplets in ccRCCs could potentially provide a viable option to target and expose ccRCCs to 
cytotoxic ER stress.  
Project Rationale: 
Previously, Gadir, et al. has shown that the cytostatic effect of rapamycin is attributed to 
the activation of TGF-b signaling pathway, resulting in p27 accumulation, followed by cell cycle 
arrest [73]. But in the same study, rapamycin could induce apoptosis if cells were pretreated with 
Aphidicolin. Aphidicolin arrests the cells at the G1/S boundary. If cells were treated with 
rapamycin after this point, cells were dying due to apoptosis even in the presence of serum/TGF-
b. After this late G1/S progression, TGF-b was not able to rescue cells by inducing p27 levels. So, 
we speculated that rapamycin has different effects in different phases of the cell cycle, working as 
a cytotoxic drug in S-phase and cytostatic in G1 phase where it activates TGF-b signaling pathway. 
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 Previously, we have observed and shown that K-Ras mutant cells, upon glutamine 
deprivation, bypass the G1 mediated late checkpoint and arrest abruptly in S-phase, unlike K-Ras 
non-mutant cells [10, 116]. Apart from providing carbon to the TCA cycle intermediates, 
glutamine also provides nitrogen to nucleotides biosynthesis. In S-phase, cells require ample 
amounts of nucleotides to replicate its genome. So, we speculated that these K-Ras mutant cells 
after bypassing G1 mediated checkpoint, enter S-phase and stall in S-phase without having enough 
nucleotides, due to lack of glutamine and glutamine derived aspartate and activation of the DNA 
damage pathway due to replicative stress. 
 In the final chapter, we investigated if there is any lipid mediated distinct checkpoint in 
late G1 along with EAAs and Q mediated checkpoints [10]. Lipids are also an important nutrient 
necessary for plasma membrane synthesis and an integral part of signaling pathways. Phosphatidic 
acid has been known to stabilize the assembly of mTOR complexes [39]. So, we speculated that 
the lipid-mediated checkpoint is the same as the mTOR mediated checkpoint. Thus, we started 







































Mutations in genes encoding regulators of mTOR, commonly provides survival signals in cancer 
cells. Rapamycin and its analogs have been used but have limited success in clinical trials to target 
survival signals provided by mTOR in a variety of human cancers. Suppression of mTOR 
predominantly causes the accumulation of cells in G1 phase of the cell cycle, whereas its effect in 
other cell cycle phases remains largely unexplored. We report here that when synchronized MDA-
MB-231 breast cancer cells are allowed to progress from G1 phase to S, rapamycin activates the 
apoptotic machinery with a concomitant increase in cell death. In Calu-1 lung cancer cells, 
rapamycin activated a feedback loop that increases the phosphorylation of Akt at Ser473 in S-
phase that mitigated rapamycin-induced apoptosis. However, sensitivity to rapamycin in S-phase 
could be reestablished if Akt phosphorylation was suppressed. We recently reported that glutamine 
(Q) deprivation causes K-Ras mutant cancer cells to aberrantly arrest primarily in S-phase. 
Consistent with observed sensitivity of S-phase cells to rapamycin, interfering with glutamine 
metabolism sensitized both MDA-MB-231 and Calu-1 K-Ras mutant cancer cells to the apoptotic 
effects of rapamycin. The effect was not observed upon rapamycin treatment, when K-Ras non-
mutant cells were arrested in G1 phase due to glutamine deprivation. Importantly, rapamycin 
induced substantially higher levels of cell death upon glutamine deprivation than that observed in 
cancer cells that were allowed to progress through S-phase after being synchronized in G1. We 
postulate that exploiting metabolic vulnerabilities in cancer cells such as S-phase arrest observed 





G1 cell cycle progression into S-phase for MDA-MB-231 and Calu-1 cells 
 
We previously reported that in the absence of TGF-b, many human cancer cells are killed by 
rapamycin [66, 73, 117, 118].  In the presence of TGF-b, rather than killing the cancer cells, 
rapamycin treatment had a cytostatic effect and these cells arrested in late G1 [10, 73].  This led us 
to propose that rapamycin preferentially killed cancer cells that passed through G1 and entered S-
phase [119].  We reported recently that Ras-driven cancer cells are more sensitive to treatments 
that target cells that have entered S-phase [120].  We chose to investigate two K-Ras-driven cancer 
cells – MDA-MB-231 breast and Calu-1 lung cancer cells, which we have used previously to 
address the vulnerability of Ras-driven cancer cells that had entered S-phase [120, 121].  We 
wanted to establish a G1 or G0 cell cycle arrest that was upstream from the late G1 site where 
rapamycin arrests cells [10].  Using serum withdrawal to arrest cancer cells in G0  is problematic 
because most cancer cells have acquired a mutation – such as Ras, which permits passage through 
the growth factor-dependent restriction point [122].  We therefore arrested the cancer cells with 
lovastatin, which causes G1 cell cycle arrest in both normal and cancer cells [123, 124].  The 
lovastatin-induced G1 arrest can be overcome with mevalonic acid and the arrest occurs relatively 
early in G1. MDA-MB-231 and Calu-1 cells were treated with lovastatin for 36 and 48 hours 
respectively. The G1 arrested cells were then released from cell cycle arrest by placing in fresh 
medium containing mevalonic acid. Mevalonic acid is the product of b-hydroxy-b-methylglutaryl-
CoA (HMG-CoA) reductase- the target of lovastatin and the rate-limiting step in cholesterol 
biosynthesis [125]. As shown in Fig. 2.1, treatment of asynchronous MDA-MB-231 and Calu-1 
cells with lovastatin resulted in a shift to a predominantly G1 population of cells. Upon changing 
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to fresh medium containing mevalonic acid to release from the lovastatin-induced G1 arrest, there 
was a shift to a predominantly S-phase population of cells between 22 and 24 hrs. (Fig. 2.1A) 
 
Figure 2.1- Cell cycle progression from G1 into S-phase for MDA-MB-231 and Calu-1 cells. 
(A) MDA-MB-231 breast cancer cells and Calu-1 lung cancer cells were plated at 30% confluence in 
medium containing 10% Fetal Bovine Serum. After 24 hours, cells were synchronized using lovastatin as 
described in Materials and Methods.  Upon release from G1 block, cells were collected at indicated time 
points and analyzed for cell cycle distribution by measuring DNA content using flow cytometry. Error bars 
represent the standard deviation for experiments repeated at least 3 times. (B) Western blot analysis 
performed to determine the levels of cyclin A, and actin. These data shown are representative of 
experiments repeated at least 3 times. 
We also examined the levels of Cyclin A, which is elevated as cells enter S-phase [126] during the 
transition from lovastatin arrest in G1 to S-phase. As shown in Fig. 2.1B, there was an increase in 
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induces G1 arrest in both MDA-MB-231 and Calu-1 cells, and upon restoring fresh medium 
containing mevalonic acid, the cells proceed to S-phase. Given that the time course was longer 
than the time required for progressing from mitosis to S, there is clearly a recovery period needed 
to reprogram progression into S-phase. 
mTOR inhibition by rapamycin enhances apoptosis in S phase of the cell cycle in MDA-
MB-231 cells but not in Calu-1 cells  
Having established a time course for progression from lovastatin-induced G1 arrest to S-phase, we 
investigated the ability of rapamycin to induce apoptosis in G1 relative to S-phase. We previously 
reported that high (20µM) doses of rapamycin that suppress phosphorylation of 4E-BP1 were 
required for rapamycin-induced apoptosis [66, 118]. MDA-MB-231 (Fig. 2.2A) and Calu-1 (Fig. 
2.2B) cells were arrested in G1 with lovastatin as in Fig. 2.1 and then released with fresh medium 
containing mevalonic acid. Upon release from lovastatin block, rapamycin was added at indicated 
times for additional 24 hours after which apoptosis was assessed by measuring increase in cleaved 
PARP levels. At 22 hours after release when the cells were entering S-phase, there was an increase 
in PARP cleavage with rapamycin in MDA-MB-231 cells (Fig. 2.2A) but not in Calu-1 cells (Fig. 
2.2B). Cell viability correlated with the levels of PARP cleavage induced by rapamycin for both 
the MDA-MB-231 and Calu-1 cells (Fig. 2.2C). The Calu-1 cells survived even though 
phosphorylation of 4E-BP1 was inhibited by rapamycin (Fig. 2.2B). Thus, rapamycin, at doses 
that suppress 4E-BP1 phosphorylation, induced PARP cleavage in MDA-MB-231 cells when they 





Figure 2.2- mTOR inhibition by rapamycin enhances apoptosis in S-phase of the cell cycle in 
MDA-MB-231 cells but not in Calu-1 cells.  MDA-MB-231 (A) and Calu-1 (B) cells were 
synchronized in G1 phase of the cell cycle using lovastatin as in Fig. 2.1.  Upon release from G1 block, 
rapamycin (20µM) was added at indicated time points.  After 24 hours, cells were collected and Western 
blot analysis was performed for cleaved PARP (Cl-PARP), P-4E-BP1(T37/46), 4E-BP1, and actin.  These 
data shown are representative of experiments repeated at least 3 times. (C) MDA-MB-231 and Calu-1 cells 
were synchronized using lovastatin as in (A) and (B). Upon release from G1 block, the cells were treated 
with rapamycin at 12 and 24 hours. Cells were collected 24 hours later and cell viability assays were 
performed using trypan blue exclusion as described in Materials and Methods. Error bars represent the 
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Combined inhibition of mTORC1 and Akt phosphorylation induces PARP cleavage in 
Calu-1 cells 
 
Figure 2.3- Combined inhibition of mTORC1 and Akt phosphorylation induces PARP 
cleavage in Calu-1 cells. Calu-1 cells were synchronized using lovastatin as in Fig. 2.1. Upon release 
from G1 block, rapamycin and LY294002 (20 µM each) were added at 12 hours (G1 phase) (A) and at 24 
hours (S phase) (B). 24 hours later, cells were collected and Western blot analysis was performed for 
cleaved PARP (Cl-PARP), P-Akt(S-473), Akt and actin. The data shown are representative of experiments 
repeated at least 2 times. (C) Calu-1 cells were synchronized using Lovastatin as above. Upon release from 
G1 block, the cells were treated with rapamycin and LY294002 at indicated times for 24 hours. Cells were 
then collected and cell viability assays were performed as in Fig. 2.2 C. Error bars represent the standard 
deviation for experiment at least repeated 2 times. 
So, in the previous data reveal that while rapamycin induced apoptosis in MDA-MB-231 cells in 
S-phase, Calu-1 cells were resistant to this treatment. We reported previously that elevated 
phosphorylation of Akt at Ser473 can inhibit rapamycin-induced apoptosis in pancreatic cancer 











































































































cells [117]. Previous reports have shown that inhibition of mTORC1 with rapamycin elevates Akt 
phosphorylation in some cancer cells including Calu-1[76, 127]. Since the Akt is well known to 
provide survival in cancer cells [128, 129], we investigated whether suppressing Akt 
phosphorylation at Ser473 would make Calu-1 cells susceptible to rapamycin. To determine that 
possibility, we investigated the effect of rapamycin in combination with the phosphatidylionositol-
3-kinase (PI3K) inhibitor LY294002, which suppresses Akt phosphorylation [117]. Calu-1 cells 
were arrested in G1 phase with lovastatin and released with fresh medium and mevalonic acid as 
in Fig. 2.1. As shown in Fig. 2.3A and 2.3B, rapamycin treatment led to elevated levels of Akt 
phosphorylation at Ser473 at both 12 and 24 hours post release from lovastatin block. There was 
a more drastic increase seen 24 hours post release and rapamycin treatment, which is consistent 
with two recent reports indicating that phosphorylation of Akt at Ser473 is more prominent in S-
phase [130, 131]. LY294002 suppressed the rapamycin-induced increase in Akt phosphorylation 
in both G1 and S-phase (Fig. 2.3A and 2.3B). Along with the suppression of Akt phosphorylation, 
there was a corresponding increase in PARP cleavage (Fig. 2.3B) and cell death (Fig. 2.3C) in the 
S-phase Calu-1 cells. The elevated PARP cleavage and cell death seen with LY294002 alone (Fig. 
2.3B and 2.3C) is likely because PI3K and mTOR are related kinases and LY294002 partially 
inhibits mTOR as well as PI3K [132]. These data explain that the feedback activation of Akt via 
suppression of mTORC1 [76, 127] suppresses the apoptotic machinery activated by rapamycin in 





Arresting K-Ras mutant cancer cells in S-phase by suppressing glutamine utilization enhances 
rapamycin-induced apoptosis  
Treating MDA-MB-231 cells with rapamycin and Calu-1 cells with rapamycin plus LY294002 
when cells were progressing through S-phase resulted in elevated levels of cleaved PARP and an 
increase in cell death (Figs. 2.2 and 2.3). However, the levels of PARP cleavage and cell death 
was not as robust as was observed if cells were deprived of serum or if they were arrested in S-
phase with Aphidicolin- an inhibitor of DNA synthesis [73]. We recently reported that K-Ras 
driven cancer cells bypass a late G1 glutamine-dependent checkpoint [10] and instead arrested in 
S-phase [116]. We therefore examined whether rapamycin, which apparently induces apoptosis in 
S-phase cells specifically, induces apoptosis in K-Ras mutant cancer cells when glutamine is 
deprived or its utilization is inhibited pharmacologically. We used two means to suppress 
glutamine in the cells: 1) using medium lacking glutamine; and 2) blocking anaplerosis utilization 
of glutamine with Aminooxyacetate (AOA), which interferes with the transamination reaction 
whereby glutamate is deaminated to a-ketoglutarate while oxaloacetate is aminated to aspartic 
acid by the enzyme called glutamate-oxaloacetate-transaminase (GOT) [133]. MDA-MB-231 and 
Calu-1, K-Ras mutant cells arrested largely in S-phase and we used MCF-7 breast cancer cells as 
a negative control- K-Ras non-mutant cells which arrest in G1 in response to glutamine 
deprivation. (Fig. 2.4A) AOA treatment mimics the growth arrest observed in K-Ras mutant cells 
as well as K-Ras non-mutant cells S and G1-phase respectively (Fig. 2.4A). We next examined the 
effect of rapamycin on MCF-7 and MDA- MB-231 cells that had been subjected to glutamine 
deprivation or AOA treatment. As shown in Fig. 2.4B, treatment of MCF-7 cells, which largely 
arrest in G1 phase, did not result in significant cell death although there was some PARP cleavage 
upon rapamycin treatment by itself- a phenomenon we have observed previously [134]. 
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Figure 2.4- Glutamine starvation causes S phase arrest in K-Ras mutant cell lines and 
sensitizes them to rapamycin. (A) MCF7, MDA-MB-231, and Calu-1 cells were plated at 30% 
confluence.  After 24 hours, cells were shifted to medium lacking glutamine or complete medium containing 
AOA (0.5 mM) for 48 hours. Cells were collected and analyzed for cell cycle distribution by measuring 
DNA content using FACS analysis. Error bars represent the standard deviation for experiments repeated at 
least repeated 3 times. (B) MCF-7 and MDA-MB-231 cells were arrested in S phase as described in (A). 



























































































































































Western blot analysis was performed for cleaved PARP, P-Akt (S473) phosphorylation and actin. Cell 
viability was determined as in Fig. 2.2C.  Error bars represent the standard deviation for experiments 
repeated 3 times.  (C) Calu-1 cells were arrested in S phase as in (A). After 48 hours, cells were treated 
with Rapamycin and LY294002 for 24 hours where indicated. Cells were then collected and Western blot 
analysis and cell viability assays were performed as in (B). Error bars represent the standard deviation for 
experiments repeated 3 times. 
This presumably reflects a subpopulation of S-phase cells in both glutamine deprivation and AOA, 
which arrest cells in G1, prevented the rapamycin-induced PARP cleavage. However, in the MDA-
MB-231 cells, rapamycin induced PARP cleavage in cells that had either been deprived of 
glutamine, or where glutamine utilization via GOT was blocked by AOA (Fig. 2.4B). For Calu-1 
cells, we employed LY294002 along with rapamycin. What was observed was somewhat 
unexpected in that both glutamine deprivation and AOA elevated Akt phosphorylation at Ser473 
and surprisingly rapamycin no longer stimulated Akt phosphorylation and, in fact, suppressed the 
phosphorylation stimulated by glutamine deprivation and AOA (Fig. 2.4C). Importantly 
rapamycin stimulated PARP cleavage and loss of cell viability in the absence of LY294002 (Fig. 
2.4C). The PARP cleavage and the loss of cell viability were substantially stronger in the cells that 
were arrested in S-phase (Fig. 2.4) than those that were passing through S-phase (Fig. 2.2 and 2.3). 
The data in Fig. 2.4 demonstrate that K-Ras mutant cancer cells that are arrested in S-phase and 
perhaps G2/M phase by interfering with glutamine utilization are highly sensitive to the apoptotic 
effects of rapamycin. 
Discussion 
 
In this study, we have provided evidence that the apoptotic effects of rapamycin occur after 
transition from G1 into S-phase of the cell cycle. Prior to enter into S-phase, rapamycin causes 
TGF-b-dependent cell cycle arrest at a site late in G1 [10]. While the apoptotic machinery was 
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clearly activated by rapamycin when cells synchronized in G1 were allowed to progress 
synchronously to S-phase, cell viability was reduced much more substantially if the cells were 
arrested in S-phase. Of significance, S-phase arrest could be accomplished in cancer cells 
harboring K-Ras mutations by interfering with glutamine utilization. Thus a synthetic lethality for 
rapamycin can be created by exploiting the ability of K-Ras mutant cancer cells to override a late 
G1 glutamine checkpoint and arrest in S-phase [116]. Thus, the cell cycle specificity for the 
apoptotic effects of rapamycin offers novel therapeutic options for the large number of K-Ras 
mutant cancers. 
 There was a complication with the rapamycin strategy resulting from a feedback activation 
of mTORC2 and the phosphorylation of Akt at Ser473. In response to suppressing the 
phosphorylation of S6K by mTORC1, there is an IGF1 receptor-dependent increase in 
phosphorylation of Akt at Ser473 [76, 127]. This was observed in Calu-1 cells used in this study 
where the feedback stimulation of Akt phosphorylation suppressed the activation of the S-phase 
apoptotic effects of rapamycin. Rapamycin did not stimulate the feedback activation of Akt in the 
MDA-MB-231 cells. We have seen a similar resistance to rapamycin-induced apoptosis created 
by induction of Akt phosphorylation in pancreatic cancer cells with defective TGF-b signaling 
[117]. In the previous study with pancreatic cancer cells, like Calu-1 cells, suppressing Akt 
phosphorylation restored the apoptotic effect of rapamycin. Thus, activated Akt can overcome the 
apoptotic effect of rapamycin on S-phase cells- consistent with its known role as a survival kinase 
[128]. It will therefore be important to know whether the feedback is active in a given cancer for 
a rapamycin-based therapeutic strategy. However, a combination of suppressing both mTORC1 
and mTORC2 could work. We used a catalytic mTOR inhibitor to achieve suppression of both 
mTORC1 and mTORC2 and induce apoptosis and pancreatic cells and cells that has feedback 
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activation loop for Akt [117]. It was also of interest and importance that in Calu-1 cells deprived 
of glutamine, rapamycin inhibited, rather than stimulated Akt phosphorylation and was able to 
induce the apoptotic effect in these cells that were arrested in S-phase. Thus, the feedback 
stimulation of Akt phosphorylation may not be an issue if a strategy that employs glutamine 
deprivation is used. 
 
Figure 2.5- Model for cell cycle-dependent sensitivity to rapamycin. (A) Rapamycin 
resistance. In most cells, the apoptotic effect of rapamycin is negated by a TGF-β-dependent late G1 cell 
cycle arrest. Additionally, a feedback dependent increase in Akt phosphorylation in Akt phosphorylation at 
Ser473 mitigates S-phase cytotoxicity of rapamycin. (B) Synthetic lethality. A synthetic lethality for 
rapamycin could be achieved via one of the 3 mechanisms: (a) in cells with defective TGF-β signaling, 
rapamycin treatment fails to arrest the cells in G1 phase and instead the cells progress into S-phase where 
rapamycin causes apoptosis. (b) Feedback activation of Akt (S473) phosphorylation in S-phase is 
suppressed with LY294002, and in absence of Akt-dependent survival signals, rapamycin induces apoptotic 
cell death. And lastly, (c) in K-Ras mutant cancer cells, blockade of glutamine utilization causes the cells 
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to aberrantly arrest in S-phase [10]. Importantly, in this case, S-phase arrest is not accompanied with an 
increase in Akt (Ser473) phosphorylation upon rapamycin treatment, and consequently, rapamycin induces 
apoptotic cell death in the absence of Akt inhibition.  
It is clear that micro-molar doses of rapamycin that suppress phosphorylation of 4E-BP1 
are required [66]. Consistent with this hypothesis, suppression of 4E-BP1 expression prevented 
the apoptotic effects of rapamycin [66]. Since the suppression of 4E-BP1 phosphorylation leads to 
the sequestration of eIF4E and repressed cap-dependent translation [48], the observations reported 
here implicate eIF4E as being critical for progression through S-phase. In this regard, it is of note 
that eIF4E can induce tumorigenesis when dysregulated and overexpressed [135]. eIF4E promotes 
the translation of proteins critical for cell cycle progression and survival [136]. Thus, when 
mTORC1 is suppressed in S-phase, the cells are getting a signal that nutrient is sparse and since 
the cell cycle is not reversible, default apoptotic signals are activated. It appears that if cells are 
progressing through the S-phase, the majority of cells are able to survive rapamycin treatment and 
the activation of the apoptotic machinery. However, if the cells are arrested in S-phase, then there 
is substantial cell death caused by rapamycin. The arrest of K-Ras mutant cancer cells in S-phase 
caused by interfering with glutamine utilization creates synthetic lethal phenotype for rapamycin. 
Thus, a therapeutic approach that blocks the anaplerotic utilization of glutamine along with 
rapamycin represents a plausible approach for treating the large number of human cancers driven 
by K-Ras mutation. 
According to our observations, cells were significantly vulnerable to rapamycin when they 
were arrested in S-phase by Aphidicolin or glutamine deprivation. Aphidicolin is a DNA 
polymerase-ɑ inhibitor, which affects the DNA replication machinery. It is not clear why 
glutamine deprivation would make cells so sensitive to cytotoxic effects of rapamycin. The next 
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chapter will focus on the investigating the molecular mechanism of the S-phase arrest caused by 

























Chapter 3: Aspartate recuses S-phase arrest mediated by DNA damage pathway caused 













During G1-phase of the cell cycle, normal cells respond first to growth factors that indicate that it 
is appropriate to divide and then later in G1, to the presence of nutrients that indicate sufficient 
raw material to generate two daughter cells. Dividing cells rely on the “conditionally essential” 
amino acid glutamine (Q) as an anaplerotic carbon source for TCA cycle intermediates and as a 
nitrogen source for nucleotides biosynthesis. We previously reported that while non-transformed 
cells arrest in the latter portion of G1 upon glutamine deprivation, K-Ras mutant cancer cells 
bypass the G1 checkpoint, and instead, arrest in S-phase. In this study, we report that the arrest of 
K-Ras mutant cancer cells in S-phase upon glutamine deprivation is due to the lack of deoxy 
nucleotides needed for DNA synthesis. The lack of deoxy nucleotides causes replicative stress 
leading to activation of the ataxia telangiectasia and Rad3-related protein (ATR)-mediated DNA 
damage pathway, which arrests K-Ras mutant cells in S-phase. The key metabolite generated from 
glutamine utilization was aspartate, which is generated from a transaminase reaction whereby 
glutamine-derived glutamate is converted to ɑ-ketoglutarate with the concomitant conversion of 
oxaloacetate and aspartate. Aspartate is a critical metabolite for both purine and pyrimidine 
nucleotides biosynthesis. This study identifies the molecular basis for the S-phase arrest caused by 
glutamine deprivation in K-Ras mutant cancer cells that arrest in S-phase in response to glutamine 
deprivation. Given that arresting cells in S-phase sensitizes cells to apoptotic insult, this study 








Deoxy nucleosides reverse the S-phase arrest caused by glutamine deprivation in K-Ras 
mutant cancer cells 
Since glutamine (Q) provides nitrogen for purine and pyrimidine nucleotides biosynthesis [137, 
138], glutamine deprivation could disrupt the pool of available nucleotides in cells by interfering 
with de novo purine and pyrimidine biosynthesis. To test this hypothesis, we subjected K-Ras 
mutant MDA-MB-231 breast cancer cells, K-Ras non-mutant MCF-7 breast cancer cells, and non-
cancerous BJ-hTERT fibroblasts to Q deprivation for 48 hours. As observed previously, the MDA-
MB-231 cells arrested in S-phase, whereas the MCF-7 and BJ-hTERT cells arrested in G1 phase 
upon Q deprivation [10, 116, 139]. (Fig. 3.1A) After 48 hours of Q deprivation, a mixture of deoxy 
nucleosides was added exogenously and cell cycle progression was monitored by flow cytometric 
analysis. As shown in Fig. 3.1A, we were able to reverse the S-phase cell cycle arrest caused by Q 
deprivation with the addition of nucleosides to the MDA-MB-231 cells. The deoxy nucleosides 
had no effect on the G1 arrested MCF-7 and BJ-hTERT cells (Fig.3.1A). These data indicate that 
the S-phase arrest of the K-Ras mutant MDA-MB-231 cells induced by Q deprivation was due to 
the depletion of deoxy nucleotides needed for DNA synthesis. 
 We next examined whether the deoxy nucleosides promoted cell proliferation in the MDA-
MB-231 cells deprived of Q. As shown in Fig. 3.1B, the addition of deoxy nucleotides promoted 
cell proliferation in MDA-MB-231, but not in MCF-7 and BJ-hTERT cells, which were arrested 
in G1 upon glutamine starvation. This finding demonstrates that providing deoxy nucleotides not 
only allows progression through S-phase, but allows cells to undergo mitosis as well. The lack of 
effect on MCF-7 and BJ-hTERT cells suggests that the Q requirement for nucleotides biosynthesis 




Figure 3.1- Reversal of S phase arrest in K-Ras mutant cells upon exogenous addition of 
nucleosides.  (A) MDA-MB-231, MCF-7 and BJ-hTERT cells were plated at 30% confluence in 10 cm 
plates in DMEM containing 10% fetal bovine serum (FBS).  After 24 hours, cells were shifted to DMEM 
containing or lacking Q for 48 hours. Both +Q and –Q medium contained 10% dialyzed fetal bovine serum. 
At this point, cells were transferred into media lacking Q with or without nucleosides. The lysates were 
collected at different time intervals and analyzed for cell cycle distribution by measuring DNA content/cell 
using flow cytometric analysis. The error bars represent S.D. for experiments repeated for two times. p 
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values for the S-phase population in MDA-MB-231, MCF-7 and BJ-hTERT cells, across the samples are 
expressed relative to control Q. (B) Cells were plated and treated as in (A). Cells were harvested at indicated 
time points, stained using crystal violet and quantified by light microscopy. Error bars represent S.D. for 
experiments repeated for two times. (C) Cells were plated in 12-well plates with 30% confluence and shifted 
to the media as explained in (A). After 48 hours of Q deprivation, cells were shifted to medium lacking Q 
with or without deoxy nucleosides (dNSs) for 24 hours. [3H]-thymine deoxyribose (TdR) (20 Ci/mMol, 1 
mCi/ml) was added for the last 2 hours of treatment. The samples were then subjected to scintillation 
counting to measure labeled DNA. Values were normalized to the cpm for +Q, which were given values of 
100%. Error bars represent S.D. for experiments repeated two times. (ns=p>0.05, *=p<0.05, **=p<0.01 
***=p<0.001, ****=p<0.0001) 
 To further establish that the deoxy nucleotides were restoring DNA synthesis, we examined 
the impact of deoxy nucleotides on DNA synthesis as indicated by the incorporation of [3H]-
thymine-deoxyribose (TdR). K-Ras mutant MDA-MB-231 breast and Calu-1 lung cancer cells 
along with the K-Ras non-mutant MCF breast cancer cells and BJ-hTERT cells were subjected to 
Q deprivation for 48 hours and then treated with the deoxy nucleosides mix for 24 hours as 
indicated. [3H]-thymine-deoxyribose (TdR) was added for the last 2 hours at which time the cells 
were harvested and the level of [3H]-(TdR) incorporation was determined. As shown in Fig. 3.1C, 
Q deprivation resulted in the suppression of 80% of the [3H]-(TdR) incorporation in all the cell 
lines. When deoxy nucleosides were provided, [3H]-TdR incorporation was restored in the S-phase 
arrested MDA-MB-231 and Calu-1 cells, but not in the G1 arrested MCF-7 and BJ-hTERT cells. 
These data demonstrate that DNA synthesis was restored by the presence of deoxy nucleosides in 
Q-deprived K-Ras driven cancer cells. 
Aspartate reverses the S-phase arrest in K-Ras mutant cancer cells 
We previously reported that we could mimic Q-deprivation with the transaminase inhibitor AOA 
[116], which blocks the conversion of Q-derived glutamate to ɑ-KG in K-Ras mutant cancer cells. 
Importantly conversion of glutamate to ɑ-KG is coupled with the conversion of oxaloacetate to  
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Figure 3.2- S-G2 phase arrest caused by inhibition of utilization of glutamine can be reversed 
by addition of nucleosides and aspartate exogenously.  (A) MDA-MB-231 and Calu-1 were plated 
at 30% confluence in 10-cm plates in complete media (CM) containing 10% FBS. After 24 hours, cells 
were shifted to medium containing or lacking 0.5 mM AOA for 48 hours. At this point, cells were 
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transferred into media containing AOA with or without dNSs. Lysates were collected after 48 hours and 
analyzed for cell cycle distribution by measuring DNA content/cell using flow cytometric analysis. Error 
bars represent S.D. for experiments repeated two times. p values for the S-phase and G2-phase population 
in MDA-MB-231 and Calu-1 cells respectively, across the samples are expressed relative to control Q. (B) 
MDA-MB-231, Calu-1 and MCF-7 cells were plated and treated with AOA for 48 hours as in (A). Along 
with AOA, cells were treated with cell permeable analogues of a-KG (DMKG; 4 mM) and aspartate (b-
MD, 10 mM).  [3H]-thymidine deoxyribose (TdR) (20 Ci/mMol, 1 mCi/ml) was added for the last 24 hours 
of the treatment. Cells were then subjected to scintillation counting to measure labeled DNA. Error bars 
represent S.D. for experiments repeated two times. (C) MDA-MB-231, Calu-1 and MCF-7 cells were plated 
and treated with AOA for 48 hours as described in (A). Along with AOA, cells were treated with the cell 
permeable analogues of a-KG and aspartate. Cells were harvested after 48 hours and analyzed for cell cycle 
distribution by measuring DNA content/cell using flow cytometric analysis. Error bars represent S.D. for 
experiments repeated two times. p values for the S-phase in MDA-MB-231; MCF-7 and G2-phase 
population in Calu-1 cells, across the samples are expressed relative to control Q. (ns=p>0.05, *=p<0.05, 
**=p<0.01 ***=p<0.001, ****=p<0.0001) 
aspartate by the enzyme GOT [90]. Thus, the inhibition of GOT with AOA suppresses not only 
the production of ɑ-KG but also Aspartate. K-Ras mutant MDA-MB-231 and Calu-1 cells were 
treated with AOA for 48 hours and as reported previously, the cells arrested in S and G2-phases 
of the cell cycle [116, 139] (Fig. 3.2B). As was observed with Q deprivation in Fig. 3.1A, the S-
phase arrest caused by AOA could be reversed with deoxy nucleosides (Fig. 3.2A). Thus, the S-
phase arrest in K-Ras mutant cancer cells induced by inhibiting Q utilization with AOA can be 
reversed by providing deoxy nucleosides. Of significance, aspartate is a critical metabolite in the 
synthesis of purine and pyrimidines. We therefore examined whether the AOA-induced S-phase 
arrest could be reversed by providing cell permeable analogues of ɑ-KG and/or aspartate- the 
products of GOT. As shown in Fig. 3.2B, aspartate especially reversed AOA-induced suppression 
of [3H]-TdR in MDA-MB-231 and Calu-1 cells, whereas ɑ-KG had very little effect. In contrast, 
both aspartate and ɑ-KG could reverse the suppression of [3H]-TdR incorporation in MCF-7 cells. 
Similar results were obtained using flow cytometry where aspartate could reverse the S-phase 
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arrest seen in the K-Ras mutant cancer cells, whereas both ɑ-KG and aspartate could only partially 
reverse the G1 arrest seen in MCF-7 cells (Fig. 3.2C). Thus, it appears that suppression of aspartate 
production by the transaminase reaction catalyzed by GOT is a key factor for inducing S-phase 
arrest in response to inhibition of Q utilization. Since aspartate is a metabolite in purine and 
pyrimidine biosynthesis, deprivation of aspartate could reduce the pool of nucleotides needed for 
DNA synthesis and cause S-phase arrest. 
Blocking nucleotide biosynthesis causes an S-phase arrest 
 
The data in Figs 3.1 and 3.2 suggest that the S-phase arrest observed in the absence of Q is due to 
lack of Q-derived purine and pyrimidine biosynthesis. We therefore demonstrated whether 
suppressing de novo purine and pyrimidine biosynthetic pathways would, like Q deprivation, also 
lead to S-phase arrest in K-Ras mutant cancer cells. A rate limiting step in the de novo biosynthetic 
pathway for purine nucleotides is conversion of 5-phosphoribosyl-ɑ-pyrophosphate and Q into 
glutamate and β-5-phosphoribosylamine, which is catalyzed by phosphoribosyl pyrophosphate 
amidotransferase (PPAT). Thus, knockdown of PPAT should block the utilization of Q for purine 
nucleotide biosynthesis and mimic Q deprivation. We therefore used siRNA targeted against PPAT 
to suppress its expression in the K-Ras mutant cancer cells as well as K-Ras non-mutant cancer 
cells. As shown in Fig. 3.3A, complete knockdown of PPAT was observed after 72 hours of 
treatment with the siRNA. At this point MDA-MB-231, Calu-1 and MCF-7 cells showed an 
increase in S-phase cell populations (Fig. 3.3B). Thus, it shows that manipulation with the de novo 
nucleotides biosynthetic pathways disrupts nucleotide pools in the cells and therefore, lead to S-




Figure 3.3- S-phase arrest upon blocking de novo nucleotide biosynthesis pathway. (A) MDA-
MB-231, Calu-1 and MCF-7 cells were plated at 60% confluence in 6-well plates in CM. After 24 hours, 
cells were transfected with either scrambled or PPAT siRNA. Western blot was performed on lysates 
collected at the indicated time points to check the levels of PPAT. The data shown are representative of 
experiments repeated two times. (B) Cells were prepared as in (A) and then shifted to fresh medium for 96 
hours. The cells were collected and flow cytometric analysis was performed for cell cycle distribution by 
measuring DNA content/cell. The error bars represent S.D. for experiments repeated two times. p values 
for the S-phase population in MDA-MB-231 and Calu-1 cells, across the samples are expressed relative to 
control Q. (ns=p>0.05, *=p<0.05, **=p<0.01 ***=p<0.001, ****=p<0.0001) 
Glutamine deprivation activates ATR-Chk1 mediated DNA damage pathway 
 
During DNA replication, cells are on high alert for DNA abnormalities such as strand breaks or 
base modifications that interfere with replicating the genome. Throughout this process, if anything 
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[99, 140]. We postulated that since Q-deprived K-Ras mutant cells lack nucleotides to replicate 
the genome, stretches of single stranded DNA would be generated from unreplicated DNA caused 
by the lack of deoxy nucleotides. Single stranded DNA breaks stimulates the ATR pathway 
whereas double stranded DNA breaks caused by ionizing radiation stimulate the ATM pathway. 
In response to unreplicated single stranded DNA, ATR phosphorylates checkpoint kinase 1 
(Chk1); and in response to double stranded breaks, ATM phosphorylates Chk2 [141]. We therefore 
examined the impact of Q deprivation on the phosphorylation of Chk1 and Chk2 in cells harboring 
K-Ras mutations and those without mutations. As shown in Fig. 3.4A, both Q deprivation and 
AOA stimulated a robust increase in Chk1, but not Chk2 phosphorylation in K-Ras mutant MDA-
MB-231 and Calu-1 cells. Neither Q deprivation nor AOA was able to induce Chk1 
phosphorylation in the MCF-7 or BJ-hTERT cells that are arrested in G1 phase of the cell cycle 
(Fig. 3.4A). These data indicate that in K-Ras mutant cells, glutamine starvation leads to 
replication stress due to insufficient precursors for deoxy nucleotides synthesis, which in turn 
causes stretches of single stranded DNA that activates the ATR mediated DNA damage pathway 
that causes S-phase arrest. In Fig. 3.1, we have shown that the S-phase arrest caused by Q 
deprivation can be rescued by addition of deoxy nucleosides. So next thing we wanted to check 
whether the stimulation of Chk1 phosphorylation by Q deprivation could be overcome with the 
addition of deoxy nucleosides. As shown in Fig. 3.4B, Addition of deoxy nucleosides will repress 
the phosphorylation of Chk1 and allows cells to progress in cell cycle. To further establish that the 
S-phase arrest observed in K-Ras mutant cancer cells upon Q deprivation was dependent on the 
ATR-Chk1 stress response pathway, we investigated whether suppression of Chk1 




Figure 3.4- Activation of ATR-mediated DNA damage pathway upon deprivation or 
inhibition of utilization of the glutamine. (A) MDA-MB-231, Calu-1, MCF-7 and BJ-hTERT cells 
were plated at 30% confluence in CM. After 24 hours, cells were transferred to medium with Q, without Q 
and medium containing Q and AOA both for 48 hours.  Cells were then collected and Western blots were 
performed for phospho-Chk1 (Ser345), phospho-Chk2 (Thr68), Chk1, Chk2, and actin. Cisplatin (10µm) 
and Hydroxyurea (5mM) treated cells were used as a positive control. The data shown are representative of 
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cm plates in CM. After 24 hours, cells were shifted to DMEM containing Q or DMEM without Q for 48 
hours. At this point, cells were transferred into media lacking Q with or without nucleosides. The lysates 
were collected after 24 hours and subjected to western blots analysis for phospho-Chk1 and Chk-1.  The 
data shown are representative of experiments repeated two times. (C) MDA-MB-231 and Calu-1 cells were 
plated at 30% confluence in 10-cm plate in CM. Next day; cells were shifted to media containing no Q 
alongside DMSO or MK-8776 (10µM) for 48 hours. Cells were then collected and cell cycle distribution 
was determined by flow cytometry. The error bars represent S.D. for experiments repeated two times. 
Western blot was also performed to check the phosphorylation of Chk-1 and total Chk-1. The data shown 
are representative of experiments repeated two times. p values for the S-phase population in MDA-MB-
231 and Calu-1 cells, across the samples are expressed relative to control Q. (D) MDA-MB-231 and Calu-
1 cells were plated at 60% confluence in 6-well plates in CM. After 24 hours, cells were transfected with 
either scrambled or Chk-1 siRNA. 48 hours later, cells were transferred to Q-deprived media another 48 
hours. Cells were then collected and cell cycle distribution was determined as above. The error bars 
represent S.D. for experiments repeated for two times. Western blot was also performed to check the levels 
of Chk-1. The data shown are representative of experiments repeated two times. p values for the S-phase 
population in MDA-MB-231 and Calu-1 cells, across the samples are expressed relative to control Q. 
(ns=p>0.05, *=p<0.05, **=p<0.01 ***=p<0.001, ****=p<0.0001) 
 We first examined the effect of the ATR kinase inhibitor MK-8776 [142], and as shown in 
Fig. 3.4C, this compound suppressed the phosphorylation of Chk1 induced by Q deprivation and 
reduced the S-phase population in both MDA-MB-231 and Calu-1 cells. We also examined the 
impact of suppressing Chk1 expression with siRNA. As shown in Fig. 3.4D, suppressed Chk1 
expression also reduced the population in both the MDA-MB-231 and Calu-1 cells when deprived 
of Q. These data further demonstrate that the S-phase arrest in K-Ras mutant cancer cells observed 
with Q deprivation is dependent on the ATR-Chk1 stress pathway. 
Discussion 
 
We previously reported that K-Ras driven cancers bypass a distinct Q-dependent late G1 
checkpoint and arrest in S-phase in response to Q deprivation [10]. Significantly, the cells arrested 
in S-phase are selectively killed by rapamycin [139] and other cytotoxic agents [116]. Thus, the 
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observation that K-Ras mutant cancer cells arrest in S-phase in response to Q deprivation has 
important clinical implications- in that K-Ras itself has been considered as undruggable [143]. In 
the study, we have identified the mechanism for S-phase arrest observed with Q deprivation. The 
lack of Q led to reduced levels of precursors needed for nucleotide biosynthesis, which induced 
replicative stress leading to an ATR and Chk1-mediated S-phase arrest. 
 The ATR/Chk1 stress response pathway responds to stretches of single stranded DNA 
caused by insufficient deoxy nucleotides. Q, a conditionally essential amino acid, serves a critical 
anaplerotic agent that feeds the TCA cycle when citrate is shuttled out of the mitochondria for 
generating cytosolic acetyl-CoA for fatty acid synthesis in dividing cells. Q can be deaminated 
twice to generate the TCA cycle intermediate ɑ-KG, which is just downstream from citrate in the 
TCA cycle. However, in K-Ras mutant cancer cells, the conversion of glutamate to ɑ-KG is 
accompanied by the conversion of oxaloacetate to aspartate in the transamination reaction 
catalyzed by GOT2 [90, 116]. Significantly, the S-phase arrest induced by inhibition of GOT2 
could be overcome largely with aspartate. ɑ-KG had little effect on the S-phase arrest induced by 
suppression of GOT2. Aspartate exits the mitochondria via the malate-aspartate shuttle that us 
usually used for shuttling electrons into the mitochondria, but is also important for generating 
cytosolic aspartate that can be contribute to redox balance and amino acid and nucleotide 
biosynthesis (Fig. 3.5) [144]. Aspartate is a critical metabolite for purine and pyrimidine 
biosynthesis. Several recent reports have similarly identified aspartate derived from several 
metabolic pathways as being critical in dividing cells for nucleotide biosynthesis including fatty 
acid metabolism [91], the urea cycle [92] and TCA cycle-derived citrate [93, 94]. Consistent with 
this role for aspartate, the S-phase arrest of K-Ras driven cancer cells caused by inhibition of GOT 
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could also be reversed with deoxy nucleosides and mimicked with suppression of nucleotide 
biosynthesis. 
 
Figure 3.5- Anaplerotic utilization of Q in K-Ras-driven cancer cells. Q is converted to 
glutamate (Glu) by glutaminase (GLS). Glu enters the mitochondria via the malate-aspartate (Asp) shuttle 
where a transaminase reaction catalyzed by GOT2 converts Glu to a-KG and oxaloacetate (OAA) to Asp.  
Asp then exits the mitochondria via the Malate-Asp shuttle where Asp can be converted to OAA by 
GOT1. OAA can then be reduced by malate dehydrogenase to malate using NADH. Malate can be 
oxidized to pyruvate with concomitant production of NADPH and maintain redox balance. Asp can also 
be used for the synthesis of purines and pyrimidines, which are needed for nucleotide biosynthesis. 
 Collectively, the data provided here reveal that the S-phase arrest observed in K-Ras 
mutant cancer cells deprived of Q is due to replicative stress created by the lack of aspartate and 
glutamine needed for deoxy nucleotides biosynthesis. Thus, strategies for targeting aspartate 
synthesis pathways may be an effective means to sensitize K-Ras driven cancer cells to drugs that 

































Lipids are important nutrients that proliferating cells require to maintain energy homeostasis as 
well as to build plasma membranes for newly synthesized cells. Previously, we have identified 
nutrient sensing checkpoints that exist in the latter part of the G1 phase of the cell cycle that are 
dependent upon essential amino acids (EAA), glutamine (Q), and finally, a checkpoint mediated 
by mTOR, which integrates signals from growth factors and nutrients. In this report, we have 
identified and temporally mapped a lipid-mediated G1 checkpoint. This checkpoint is located after 
the Q checkpoint and before the mTOR-mediated G1 checkpoint. Intriguingly, clear cell renal cell 
carcinoma cells (ccRCC) have a dysregulated lipid-mediated checkpoint. When deprived of lipids, 
instead of arresting cells in G1, these cells continue to cycle and utilize lipid droplets as a source 
of lipids. Lipid droplets have been known to maintain endoplasmic reticulum (ER) homeostasis 
and prevent cytotoxic ER stress in ccRCCs. Dysregulation of the lipid-mediated checkpoint forces 
these cells to utilize lipid droplets, which could potentially lead to therapeutic opportunities that 











Depriving cells of lipids arrests cells in G1 
 
It was recently reported that Ras-driven cancer cells have an acute need for exogenously supplied 
lipids [145, 146].  During the course of this study, we noticed that non-Ras-driven cancers were 
arrested in G1 [146].  We extended this study to the immortalized human fibroblast cell line BJ-
hTERT.  We subjected these cells to serum deprivation and rapamycin for 48 hours which we 
demonstrated previously arrested the BJ-hTERT cells in G1 [10].   
 
Figure 4.1- Depriving cells of lipids arrests cells in G1.  (A) BJ-hTERT cells were plated at 30% 
confluence in DMEM containing 10% FBS. After 24 hours, cells were shifted to complete medium (CM), 
no growth factors (-GF), medium containing 10% delipidated serum (-Lipids), or CM containing rapamycin 
(+Rapa) for 48 hours. After which, the cells were harvested and analyzed for cell cycle distribution by 
measuring DNA content/cell.  The CM contained 10% dialyzed FBS instead of 10% FBS.  Error bars 
represent the standard deviation from independent experiments repeated for 3 times.  (B) BJ-hTERT cells 
were plated and shifted to conditions explained above. Cells were labeled with [3H]-TdR for the final 24 
hours of treatment, after which the cells are collected and the incorporated label was determined by 
scintillation counting. Values were normalized to the cpm for CM, which was given a value of 100%. Error 
bars represent the standard deviation for experiments repeated for 3 times. 
As shown in Fig. 4.1A, these treatments caused a G1 cell cycle arrest as determined by 
flow cytometry, which measures the DNA content per cell.  There was an increase in cells with 
A B
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G1 DNA content and reduction in the amount of S-phase and G2/M DNA content indicating a G1 
arrest.  We also treated the BJ-hTERT cells with delipidated serum and observed a similar increase 
in G1 DNA content and reduction in S-phase and G2/M DNA content cells (Fig. 4.1A) – indicating 
a G1 arrest.  We also measured the effect of lipid deprivation on DNA synthesis as measured by 
the uptake of [3H]-TdR.  The BJ-hTERT cells were treated as in Fig. 4.1A except that [3H]-TdR 
was added for the last 24 hours of treatment.  As shown in Fig. 4.1B, [3H]-TdR incorporation was 
dramatically reduced with all three treatments.  While the reduction in [3H]-TdR with delipidated 
serum was not quite as strong, this was likely due to the inability to remove all lipids from serum.  
These data demonstrate that in response to lipid deprivation, BJ-hTERT fibroblasts arrest in G1.   
Lipid deprivation arrests cells downstream of the Q checkpoint and upstream of the 
mTOR checkpoint 
In order to temporally distinguish the lipid G1 cell cycle arrest from the arrest caused serum 
withdrawal, EAA and Q deprivation, and rapamycin, we performed a series of sequential blocking 
experiments.  In brief, cells were exposed to various blocking conditions for 48 hours to cause 
complete cell cycle arrest.  At this point, the first block was removed and a second block was 
applied along with [3H]-TdR for 24 hours.  If the second block applied is either at the same point 
or downstream of the first block, then [3H]-TdR incorporation should not occur.  However, if the 
second block site is upstream of the first block, then the cells should progress into S-phase and 
incorporate the label.  The level of [3H]-TdR incorporated by cells released into complete medium 
after a first block was considered to be 100%.  We first examined cell cycle progression after a 
first block of serum withdrawal (Fig. 4.2A).  To better distinguish the effect growth factors from 
lipids in serum, the serum withdrawal block included a mixture of lipids (No GF + lipid mix) (see 
Experimental Procedures).  As reported previously [10], EAA and Q deprivation, as well as 
rapamycin treatment prevented significant [3H]-TdR incorporation.  If we used delipidated serum 
(i.e. growth factors without lipids) as a second block there was still very little [3H]-TdR (Fig. 4.2A).  
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These data indicate that the lipid checkpoint is downstream from the growth factor-dependent 
restriction point.  
 
Figure 4.2- Lipid deprivation arrests cells downstream of the Q checkpoint and upstream 
from the mTOR checkpoint.  BJ-hTERT cells were plated and shifted to various first blocking 
conditions for 48 hours as in Fig. 1A. The cells were subsequently shifted to complete medium (CM) or 
different second block conditions containing [3H]-TdR for 24 hours, after which the cells were collected 
and the incorporated label was determined.  First blocks were: (A), no serum (no growth factors) plus lipid 
mix (see Experimental Procedures); (B), no EAA; (C), no Q; (D), delipidated serum; (E), rapamycin (20 












































































































































































summarizing results from the double block mapping experiments for metabolic checkpoints for EAA, Q, 
and lipids that are hypothesized to represent a mammalian START (mSTART).  Also shown are the relative 
positions of the two restriction points (R1 and R2) that respond to growth factors that have been described 
[3, 147].   
We next examined the effects of EAA (Fig. 4.2B) and Q (Fig. 4.2C) deprivation as a first 
block.  In both cases, a second block with delipidated serum still prevented [3H]-TdR incorporation 
– indicating that the lipid checkpoint was downstream from both the EAA and Q checkpoints.  As 
reported previously [10], the Q site was downstream from the EAA site as indicated by the ability 
of Q deprivation to prevent [3H]-TdR incorporation when EAAs were restored (Fig. 4.2B); 
whereas, deprivation of EAA as a second block did not suppress [3H]-TdR incorporation if the 
first block was Q deprivation (Fig. 4.2C).  If the first block was delipidated serum, the re-addition 
of non-delipidated serum and a second block with either EAA, Q, or growth factor deprivation did 
not suppress [3H]-TdR incorporation (Fig. 4.2D).  In contrast, rapamycin treatment did prevent 
[3H]-TdR incorporation observed when non-delipidated serum was provided (Fig. 4.2D).  And 
lastly, if the first block was rapamycin, a second block with delipidated serum did not prevent 
[3H]-TdR incorporation (Fig. 4.2E) - indicating that the lipid checkpoint is upstream from the 
mTOR-dependent checkpoint.  Collectively the data in Fig. 4.2 demonstrate that the site in G1 
where cells arrest in response to lipid deprivation is between the Q checkpoint and the mTOR 
checkpoint (Fig. 4.2F). 
Effect of Lipid deprivation on cancer cell proliferation and cell cycle progression 
 
We previously reported that cancer cells harboring Ras mutations bypassed the Q checkpoint and 
arrested in S-phase instead [10, 116]. We therefore examined the impact of lipid deprivation on 
several human cancer cell lines to determine whether there are similar bypasses of the G1 lipid 
checkpoint. We examined the impact of lipid deprivation on MDA-MB-231 and MCF-7 breast,  
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Figure 4.3- Effect of lipid deprivation on cancer cell proliferation and cell cycle progression.  
(A-F) MDA-MB-231, Calu-1, DU-145, MCF-7, 786-O and RCC4 cells were plated at 30% confluence in 
CM in 10 cm plates. After 24 hours, cells were shifted to complete medium (CM) or medium containing 
delipidated serum for 48 hours, at which time the cells were harvested, fixed, stained with propidium iodide, 
and analyzed for distribution in G1 and S-phase of the cell cycle by measuring DNA content/cell as 
described in Experimental Procedures.  The percentage of G1 and S-phase cells in CM relative to that in 
delipidated serum is presented.  Error bars represent the standard deviation from experiments repeated 3 
times. (G) The cells were plated in CM in 12-wells plate and treated with conditions as explained in A. 






the incorporated label was determined by scintillation counting. Values were normalized to the cpm for 
CM, which was given a value of 100%. Error bars represent the standard deviation for experiments repeated 
for 2 times. (H) MDA-MB-231 and 786-O cells were plated in CM as above.  After 24 hours, cells were 
shifted to medium containing 10% delipidated serum.  At indicated time points, cells were harvested, and 
counted using Crystal Violet die. Error bars represent the standard deviation from experiments performed 
for 2 times. (ns=p>0.05, *=p<0.05, **=p<0.01, ***=p<0.001, ****=p,0.0001) 
Calu-1 lung, DU-145 prostate, 786-O and RCC4 renal cancer cell lines. As shown in Fig. 4.3, 
MDA-MB-231 breast (Fig. 4.3A), Calu-1 lung (Fig. 4.3B), DU-145 prostate (Fig. 4.3C), and 
MCF-7 (Fig. 4.3D) cancer cells all displayed an increase in G1 DNA content and a reduction in S-
phase DNA content in response to lipid deprivation- indicating the G1 cell cycle arrest. However, 
both 786-O (Fig. 4.3E) and RCC4 (Fig. 4.3F) renal cancer cell lines do not arrest in G1 as indicated 
by a reduced levels of cells with G1 DNA content. While there tended to by somewhat higher 
levels of cell with S-phase content with lipid deprivation in the renal cancer cell lines (Fig. 4.3E 
and 4.3F), the cells were not arrested in S-phase as indicated by continued DNA synthesis and 
uptake of [3H]-TdR in the 786-O and RCC4 cells. In addition, 786-O cells continued proliferation 
leading to increased cell number in delipidated serum; whereas MDA-MB-231 cells ceased 
proliferation in delipidated serum (Fig. 4.3H). However, after 4 days, the 786-O cells started to 
die. Thus, unlike the S-phase arrest observed with Q deprivation in Ras-driven cancer cell line [10, 
116], the renal cancer cells did not arrest in S-phase in response to lipid deprivation. 
Effect of prolonged lipid deprivation on clear cell renal cancer cells 
 
Both of the renal cancer cell lines used have a defect in the Von-Hippel Lindau (VHL) which leads 
the stabilization of hypoxia-inducible factor (HIF)1ɑ and HIF2ɑ (RCC4) or just HIF2ɑ (786-O).  
We therefore examined the impact of lipid deprivation on cell cycle progression in 786-O with 
restored VHL expression.  We found that 786-O cells with restored VHL expression were not 
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arrested in G1 (Fig. 4.4A).  Consistent with this observation, 786-O cells with restored VHL 
expression still incorporated [3H]-TdR under conditions of lipid deprivation (Fig. 4.4B).  Thus, 
the mechanism of bypass apparently does not depend on loss of VHL and stabilized HIF2ɑ.  
However, we did notice a difference between the 786-O and the 786-O cells with restored VHL 
expression in response to lipid deprivation.  If the cells are allowed to proliferate in delipidated 
serum, they ultimately die, however the cells with restored VHL died sooner than the parental 786-
O cells.  Consistent with this observation we saw an increase in sub G1 DNA content in the 786-
O-VHL cells earlier than in the 786-O cells (Fig. 4.4D) – indicating an earlier loss of cell viability 
when VHL expression was restored.  A hallmark of clear cell renal carcinoma cells is a high 
concentration of lipid droplets that is dependent upon the loss of VHL that gives these cells the 
clear cell phenotype [115].  So, next we planned to check the levels of lipid droplets in 786-O 
Mock and 786-O VHL expressed cells and we found that cells that stably express VHL protein has 
less lipid droplets as compared to its counter parts (Fig. 4.4C). Thus, it is possible that the basis 
for the lack of arrest is the utilization of the high lipid content of the HIF2ɑ-dependent 
accumulation of lipid droplets in 786-O cells.  To examine the effect of proliferation in delipidated 
serum on the level lipid droplets, we quantified the level of lipids by staining the 786-O cells with 
Oil Red O stain followed by extraction and then testing for absorbance at 492 nm to quantify the 
level of lipids in cells maintained for 48 hours in complete medium, medium with delipidated 
serum, and delipidated serum and the lipid mix.  As shown in Fig. 4.4E, the cells maintained in 
delipidated serum for 48 hours had a 65% reduction in lipid content. Since lipid metabolism is 
regulated by autophagy [148], we examined the ability of lipid deprivation to induce expression 
of the autophagy marker LC3B II.  MDA-MB-231 cells, BJ-hTERT, and 786-O cells were 
maintained in complete medium, delipidated medium, or delipidated medium plus the lipid mix 
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for 48 hours at which time the levels of LC3B II were determined by Western blot analysis.  As 
shown in Fig. 4.4F, only the 786-O cells showed an increase in LC3B II expression upon lipid 
deprivation.   
 
Figure 4.4- Renal cancer cells utilize lipid droplets to progress through the cell cycle.  (A) 786-
O-VHL cells were plated in DMEM containing 10% FBS (CM).  After 24 hours, cells were shifted to 
complete medium (CM) or medium containing 10% delipidated serum for 48 hours. The cells were then 
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cycle by measuring DNA content/cell as described in Fig. 1.  Error bars represent the standard deviation 
from experiments performed for 2 times (ns=p>0.05, *=p<0.05, **=p<0.01, ***=p<0.001, 
****=p<0.0001).  (B) 786-O Mock and VHL cells were plated in 12-well plates at 30% confluence in CM. 
After 24 hours, cells were shifted to CM or medium containing delipidated serum for 48 hours. Cells were 
labeled with [3H]-TdR for the final 24 hours of treatment, after which the cells are collected and the 
incorporated label was determined by scintillation counting. Values were normalized to the cpm for CM, 
which was given a value of 100%. Error bars represent the standard deviation for experiments repeated for 
3 times. (C) 786-O-Mock and 786-O-VHL cells were plated in CM as above.  After 24 hours, cells were 
shifted to medium containing 10% delipidated serum. After 48 hours, cells were stained with Oil Red O as 
described in Experimental Procedures. Error bars represent the standard deviation from experiments 
performed three times. (D) 786-O-Mock and 786-O-VHL cells were plated in CM as above.  After 24 hours, 
cells were shifted to medium containing 10% delipidated serum. At indicated time points, cells were 
harvested, fixed, stained with propidium iodide, and analyzed for sub-genomic DNA content/cell as 
described in Experimental Procedures at the indicated times. Error bars represent the standard deviation 
from experiments performed for 2 times. (E) 786-O cells were plated at 40% confluence in RPMI-1640 
medium containing 10% FBS for 24 hours. Cells were then shifted to CM, medium containing delipidated 
serum or medium containing delipidated serum with lipid mix added. After 48 hours, cells were stained 
with Oil Red O as described in Experimental Procedures. Error bars represent the standard deviation from 
experiments performed three times. (F) MDA-MB-231, BJ-hTERT and 786-O cells were plated and treated 
as explained earlier. Cells were harvested after 48 hours of treatment. The levels of LC3B II and actin were 
determined by Western blot analysis. The data shown are representative of experiments repeated at least 2 
times (C= Complete medium, D= Delipidated serum, D+L= Delipidated serum with lipid mix). 
Collectively, the data in Fig. 4.4 demonstrate that restoring VHL in 786-O cells does not 
reestablish a G1 arrest upon lipid deprivation; however, the data do suggest that the high lipid 
content in the 786-O cells contributes to the bypass of the G1 lipid checkpoint and prolong the 
survival of cells that continue to proliferate when deprived of lipids. 
Discussion 
In this report, we have characterized and mapped a distinct G1 cell cycle checkpoint that 
is dependent on lipids.  This checkpoint is in late G1 and appears to be grouped with two other 
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metabolic checkpoints that monitor the presence of EAAs and Q.  As shown in Fig. 4.2F the lipid 
checkpoint maps between the Q checkpoint and the checkpoint mediated by mTOR.  We are 
proposing that this collection of distinguishable late G1 metabolic checkpoints represent the 
evolutionary equivalent of START of the yeast cell cycle [4, 149].   
The metabolic checkpoints are flanked by growth factor-dependent checkpoints – the 
restriction point [150, 151], and the mTOR-dependent checkpoint [6, 147, 152].  Both of these 
growth factor dependent checkpoints have been referred to as a restriction point [122, 147, 151], 
but they are clearly distinguishable [10].  A significant difference between the two growth factor-
dependent checkpoints is the point from which you are coming.  If you are coming from mitosis, 
you need growth factors to get past the first restriction point, which is about 3.5 hours after mitosis 
[153].  However, if you are coming from quiescence or G0, you need growth factors, such as 
platelet-derived growth factor, to exit G0; and additional growth factors such as insulin-like growth 
factor for progression through late G1 [154].  If you are coming from mitosis, there is no apparent 
need for growth factors in late G1.  However, rapamycin will arrest cells that are coming from 
mitosis [10, 152] – indicating that there is a mechanism for activating mTOR that does not need 
growth factors present. 
 mTOR has been referred to as an integrator of both growth factor and nutrient signals and 
a controller of cell growth [6, 15].  mTOR has for a long time been known as a sensor of amino 
acids [155] and much has been learned recently about the mechanism for amino acids  sensing by 
mTOR [156].  It has also been proposed that mTOR can respond to both glucose and fatty acids 
via the de novo biosynthesis of phosphatidic acid [157, 158] – a metabolite that is critical for the 
stability of the mTOR complexes mTORC1 and mTORC2 [39].  It has also been reported that 
mTOR can be activated in a manner that is dependent on lysophosphatidic acid acyltransferase 
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[159] – a key enzyme in the de novo biosynthesis of phosphatidic acid.  Phosphatidic acid is also 
a product of glycolysis and therefore can be an indicator of glucose sufficiency.  Q is commonly 
converted into fatty acids that can be incorporated phosphatidic acid [160], and thusly, 
phosphatidic acid can also be an indicator of sufficient Q.  Thus, there are several mechanisms by 
which mTOR can respond to the same nutrients that are recognized additional metabolic 
checkpoints that are distinguishable from the mTOR checkpoint, which also needs growth factor 
input as well.  The question that emerges from these observations is: why is there an apparent 
redundancy of nutrient sensing mechanisms?  The finding reported here that there is a distinct 
mechanism for sensing lipids compliments the ability to sense EAAs and Q – all of which are 
critical sources of carbon and nitrogen needed for cell growth.  Clearly the cell needs to monitor 
the presence of nutrients carefully before committing to replicating the genome and doubling its 
mass.  The redundant mechanisms for nutrient sensing underscore the importance of this cellular 
function. 
 In our previous studies characterizing the Q checkpoint in cancer cells, we made the 
discovery that Ras-driven cancer cells bypassed this late G1 checkpoint and instead arrested in S-
phase [10] due to a need for Q in nucleotide biosynthesis [161].  Of significance, this created a 
synthetic lethality for rapamycin [116], which preferentially induces apoptosis in cells arrested in 
S-phase [139, 162].  In this report, we identify renal cancer cells as having a defective lipid 
checkpoint.  Two renal cancer cell lines were shown to bypass the lipid checkpoint and continue 
to divide.  These renal cancer cells are deficient in the VHL gene that encodes a ubiquitin ligase 
for HIFa [163].  HIFa is a transcription factor that promotes a metabolic transformation that causes 
lipid droplet accumulation in renal cancer cells that gives them a “clear cell” phenotype [164].  
Restoration of the VHL gene did not restore sensitivity to lipid deprivation.  However, it 
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diminished the amount of lipid in the cells and shortened the number of cell divisions before cell 
death in response to lipid deprivation.  These findings indicate that the override of the G1 lipid 
checkpoint involved more than loss of VHL and HIFa stabilization.  Thus, while this study does 
not reveal a mechanistic basis for the G1 arrest in response to lipid deprivation, an important point 
that emerges is that the ability to override the lipid checkpoint by renal cancer cells helps to 
validate the existence of this lipid checkpoint.  The override of this checkpoint in renal cancer cells 











































Based on the rationale presented in chapter 1, we were able to show that rapamycin was 
able to induce apoptosis when cells are in S-phase of the cell cycle, but not when they were in G1-
phase (Chapter 2). However, we observed a profound effect of rapamycin when cancer cells were 
arrested in S-phase over cells progressing through S-phase. Previously, we had shown that K-Ras 
mutant cancer cells override the G1 phase of the cell cycle and instead arrest in S-phase. When we 
treat cells with rapamycin in glutamine deprived K-Ras mutant cells, we witnessed an intense 
apoptotic effect of rapamycin. We did not observe the same effect in wild type K-Ras cells where 
cells were undergoing a G1 arrest, mediated by TGF-b. Previous data shown by Gadir et al., 
demonstrated that if cells are arrested in G1/S boundary using Aphidicolin, cells undergo 
apoptosis. Aphidicolin is an inhibitor of DNA replication process via inhibition of DNA pol-a. So 
we speculated that rapamycin has a more profound apoptotic effect when cells are under replication 
stress. Next we investigated if deprivation of glutamine plays any role in causing replicative stress 
in K-Ras mutant cells. 
So, in chapter 3, we have shown that S and G2-phase arrest, caused by either deprivation 
or perturbing metabolism of glutamine, was rescued by addition of nucleosides. Glutamine as well 
as aspartate generated from glutamine metabolism, both play a crucial role in de novo nucleotide 
biosynthesis. The S-phase arrest is due to activation of the ATR-Chk1 DNA damage pathway. 
This observation may shed a light on why rapamycin works more effectively on cells arrested in 
S-phase, rather than capable of progressing through S-phase. The questions that arise from these 
observations are: Why is activated mTOR necessary during the replication process? Are DNA 
damage pathways regulated by mTOR activation? Does mTOR activate any repair mechanism(s) 
to rectify the arrest in S-phase? Also, we have shown that activation of K-Ras pathway leads to 
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this phenotype observed in these cells but it would be interesting to show how activation of the K-
Ras pathway leads to override of G1 checkpoint resulting in S-phase arrest. 
In chapter 4, like amino acid and glutamine mediated late G1 nutrient sensing checkpoints, 
we mapped a lipid mediated checkpoint. Lipids are also an important nutrient that provides 
building blocks to synthesize plasma membranes and are also used as signaling molecules. We 
mapped the lipid-mediated checkpoint after the glutamine-mediated checkpoint and before the 
mTOR-mediated growth checkpoint. Clear cell renal carcinomas have dysregulated lipid-mediated 
checkpoint and do not arrest upon lipid deprivation. Due to constitutively activated HIFs, these 
cells have lipid droplets for which reason they are named “clear cell”. Restoration of the VHL 
tumor suppressor was not enough to restore this lipid-mediated checkpoint. However, restoration 
of VHL led to an early onset of cell death, which might be due to loss of clear cell phenotype. It 
would be interesting to know whether along with VHL, are there any other signaling pathways 
responsible to override the lipid-mediated checkpoint? One possibility is PTEN as 786-O cells 
lack functional PTEN. 
The work presented here shows widespread metabolic dysregulation such as override of 
glutamine-mediated checkpoint in K-Ras mutant cells and the lack of lipid-mediated checkpoint 
in clear cell renal carcinomas. Thus, exploiting these vulnerabilities could offer innovative 





























Cells and cell culture conditions 
The human cancer cell lines MDA-MB-231, MCF-7, BJ-hTERT, Calu-1, DU-145, 786-O and 
RCC-4 cells were obtained from the American Tissue Type Culture Collection (ATCC). The 786-
O-VHL cells were generated as described previously [165]. All the cells except 786-O were 
maintained in Dulbecco’s modified Eagle medium (DMEM) (Sigma, D6429) supplemented with 
10% fetal bovine serum (Sigma, F4135). 786-O cells were maintained in RPMI-1640 (Sigma, 
R8758) supplemented with 10% FBS. 
Antibodies and reagents 
Antibodies against cleaved poly-ADP-ribose polymerase (PARP) (Catalog#9541), Akt, phospho-
Akt (S473) (#9271), 4EBP1 (#9452), phospho-4EBP1 (T37/46) (#9459), Cyclin A (#4656), 
phospho-Chk1 (Ser345) (#2348), phospho-Chk2 (Thr68) (#2197), Chk1 (#2360), Chk2 (#2662), 
LC-3B (2775) and actin (#8457) were obtained from Cell Signaling; Antibody against PPAT 
(HPA036092) was obtained from Atlas Antibodies; anti-mouse and anti-rabbit HRP conjugated 
secondary antibodies were obtained from Promega. For the Glutamine deprivation, Dulbecco’s 
modified Eagle medium without Q (D5546), dialyzed fetal bovine serum (F0392), L-glutamine 
(G7513), Aminooxyacetate (AOA) (C13408), Di-methyl ɑ-ketoglutarate (DMKG) (349631) and 
aspartate (β-MD) (A8291) were obtained from Sigma-Aldrich. Rapamycin (R-5000) was obtained 
from LC Laboratories; Torin1 (4247) and lovastatin (1530) were obtained from Tocris 
Biosciences; mevalonate (M4667) was purchased from Sigma. MK-8776 (sc364611) was obtained 
from Santa-Cruz Biotechnology. Negative control scrambled siRNA (D-001206-13-05), siRNAs 
targeted against Chk1 (M-003255-04-0005) and siRNAs targeted against Phosphoribosyl 
Pyrophosphate Amidotransferase (PPAT) (M-006003-01-0005) was obtained from Dharmacon. 
	 70 
Deoxy nucleosides (dNSs) (ES-008-D) was purchased from EMD Millipore. Ultima Gold 
scintillation fluid (6013681) and [3H]-thymidine deoxyribose (TdR) (20Ci/mMol, 1mCi/ml) 
(NET-027E) were obtained from PerkinElmer. For the EAAs deprivation; DMEM lacking Arg, 
Leu and Lys (D9443) and dialyzed FBS (DFBS) (F0392) were ordered from Sigma. For the Q 
deprivation, DMEM lacking Q (D5546) and DFBS were used from Sigma. For the lipid 
deprivation; delipidated fetal bovine serum (900-123) was obtained from Gemini-Bioproducts, 
Fatty acid mixture (11905) was obtained from Invitrogen and fatty acid free bovine serum albumin 
(BP9704) was obtained from Fisher Scientific. 
Cell cycle synchronization and flow cytometric analysis 
Activated 10 mM lovastatin stock solution was prepared by dissolving 10 mg lovastatin in 200 µl 
of 95% ethanol, 156 µl of 1N NaOH was then added, pH adjusted to 7.2 using 1M HCl, and finally 
diluted to 2.5 ml with sterile-filtered water. After lovastatin treatment, cells were released from 
Lovastatin block and plated in complete medium and mevalonic acid, cell cycle distribution was 
determined as described previously [10].  Briefly, cells were fixed in 70% ethanol, stained using 
propidium iodide, and passed through 70-µm meshes to remove cell aggregates.  Fluorescence 
intensity corresponding to DNA content in different phase of cell cycle was measured by flow 
cytometry (FACSCalibur; Becton Dickinson), and analyzed using WinCycle software (Phoenix 
Flow Systems).  
Western blot analysis 
Proteins were extracted from cultured cells in M-PER (Thermo Scientific 78501). Equal amounts 
of proteins were subjected to SDS-PAGE on polyacrylamide separating gels. Electrophoresed 
proteins were then transferred to nitrocellulose membrane. After transfer, membranes were 
	 71 
blocked in an isotonic solution containing 5% non-fat dry milk in PBS. Membranes were then 
incubated with primary antibodies as described in the text. Depending on the origin of the primary 
antibody, either anti-mouse or anti-rabbit HRP conjugated IgG was used for detection using ECL 
system (Thermo Scientific 34080). The dilutions of the antibodies were used as per the 
recommended concentrations by the seller. 
Cell viability 
Cell viability was determined by trypan blue exclusion. Cells were harvested, washed and treated 
with trypan blue (Sigma-T8154) at a concentration of 0.4%v/v. After 5 min, trypan blue uptake 
(dead cells) was scored using a hemocytometer. 
Transient transfections 
Cells were plated in 6-well plates in medium containing 10% FBS. The next day, transfections 
with siRNAs (100nM) in Lipofectamine RNAi max were performed. After 6 hours, reagents were 
replaced with fresh 10% FBS and cells were allowed to incubate for indicated times as explained 
in the experiments. 
Flow cytometric analysis 
Cell cycle distribution was determined by flow cytometry as explained in [10]. Each experiment 
was performed in duplicate and two-way ANOVA tests were performed in all statistical analyses. 





Thymidine incorporation assay 
Cells were labeled with 1 µCi/ml [3H]-thymidine deoxyribose (TdR). At indicated times, cells 
were washed twice with 1ml phosphate-buffered saline and then precipitated twice with 1ml 10% 
trichloroacetic acid. The precipitates were solubilized in 0.5ml of 0.5% SDS/0.5MNaOH solution, 
and the extent of TdR incorporation was quantified using 75 µl of sample and 3 ml of scintillation 
fluid. Each experiment was performed in duplicate and one-way ANOVA tests were performed in 
all statistical analyses. 
Lipid (Oil Red O) staining 
Lipid (Oil Red O) staining kit (MAK194) was purchased from Sigma. The staining was conducted 
as per the vendor’s protocol. To measure quantitatively, stained cells were washed 3 times with 
60% isopropranolol for 5 min each time with gentle rocking. Oil Red O stain was extracted with 
100% isopropranolol for 5 min with gentle rocking. Absorbance at 492nm was measured for the 
collected samples and 100% isopropranolol was used as background to subtract the background 
signal. 
Lipid mix supplementation 
Fatty acid mix was obtained from Invitrogen (11905) and was supplied to cells as 1:200 dilution 
complexed with 10% bovine serum albumin (BSA) (Sigma) in 2 to 1 ratio for the final 
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